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論 文 概 要  
目    的： 
われわれの研究室では、睡眠覚醒制御に関わる新規遺伝子を同定するために５０００匹以上
のランダム点突然変異マウスのスクリーニングを実施してきた。その過程で、変異マウスの
中に顕著な肥満を呈するものが少数認められた。これらの変異マウスは、化学変異原である
エチルニトロソウレアを投与した雄と野生型雌との交配で得られたマウスであるため、遺伝
子変異が肥満を惹き起こしたとすれば、その遺伝子変異は肥満を惹き起こす優性変異と考え
られる。しかしながら、これまでランダム点突然変異マウスのスクリーニングによって、肥
満を惹起する劣性変異はいくつか報告があるものの、優性変異については報告がない。 
  これまで、肥満マウスの優性スクリーニングが成功していない理由として、次の２
つが考えられる。１）変異を導入するストレインとカウンターストレイン間の量的形質座位
（quantitative trait locus）の影響のために、肥満家系の樹立や表現型に基づく遺伝子型の類
推が困難である。２）肥満マウスは妊孕性が低下するため、肥満家系の樹立と維持が困難で
ある。また、フォワード・ジェネティクス一般の大きな欠点は time‐consuming であること
であり、研究が順調に進展した場合でも遺伝子を同定するまでに数年以上の時間がかかると
いう問題がある。 
  われわれの優性スクリーニングの研究では、変異ストレインとカウンターストレイ
ンとして C57BL/6（B6)サブストレインである B6J と B6N を用いているため、量的形質 座位
の影響は無視できる。また、次世代作成には自然交配ではなく体外受精を行いているので、
妊孕性の低いマウス家系も維持できる。さらに、次世代シーケンス技術の進展により全エク
ソームシーケンスを用いた変異同定が可能となったことによる全工程の時間短縮が可能とな
った。このように、われわれのスクリーニングスキームでは、肥満の優性変異スクリーニン
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グ遂行における障壁がクリアされていることから、スクリーニングで見出された肥満マウス
の次世代を作成し、肥満の優性スクリーニングを実施した。 
  研究の目的は２つある。１つは、我々の優性スクリーニングスキームの有効性検討
である。過去に成功していない肥満の優性スクリーニングに成功すれば、我々のスクリーニ
ングスキームが有用なものであり、肥満以外の表現型にも援用できる可能性を示唆する。も
う１つの目的は、優性に肥満を惹起する遺伝子変異の同定である。この遺伝子がこれまでエ
ネルギー代謝への関与が知られていないものである場合、肥満形成に関与する新たな分子を
同定することになる。 
対象と方法： 
８－１０週齢の雄 B6J マウスにエチルニトロソウレアを２回腹腔内投与した。その後１０週
以上経過して、妊孕性が回復した後に、野生型雌マウス卵と体外受精を行った。次世代マウ
スの３割以上が肥満を示した場合に、遺伝性があると判定した。肥満家系の N2 世代マウス
（B6J を B6N に２回戻し交配）を用いて、連鎖解析を行った。連鎖解析には最近公表された
B6J と B6N 間の一塩基多型データを用いた。全エクソームシーケンスはつくば i‐Laboratory
に委託した。マウスの体重、血糖、インスリン、レプチンを測定した。また、視床下部より
RNA を調整し、定量的 PCR により視床下部の神経ペプチドの定量をおこなった。SIM1 と
ARNT2 による転写活性を検討するため、ルシフェラーゼアッセイを行った。 
結    果： 
ランダム点突然変異を持つマウスの中から、１０、１８、２８週齢において最も肥満したマ
ウスを合計１３匹選んだ。体外受精によって次世代を作成したところ、１３家系のうち２家
系で約半数の個体が肥満を示した。他の家系には、肥満の遺伝は認められなかった。遺伝性
の肥満を示す２家系の連鎖解析を行ったところ、１０番染色体と１８番染色体に連鎖が認め
られた。全エクソームシーケンスにより、１０番染色体上の連鎖領域に Sim1 遺伝子の変異
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が、１８番染色体上の連鎖領域に Mc4r 遺伝子の変異が認められた。遺伝子変異は SIM1 蛋
白質 PAS ドメイン内のアミノ酸置換をもたらし、変異型 SIM1 蛋白質はルシフェラーゼアッ
セイにおいて転写活性を全く示さなかった。一方、Mc4r 遺伝子の遺伝子変異は、第一膜貫
通ドメイン直前に終止コドンをもたらす。 
Sim1 ヘテロ変異、Mc4r ヘテロ変異、高脂肪食誘導性肥満という機序の異なる肥満モデルマ
ウスの視床下部において、摂食行動やエネルギー代謝に関与する神経ペプチドの発現を検討
したが、肥満モデルごとに全く異なる傾向であった。 
考    察： 
C57BL/6 サブストレインを使用することで、はじめて肥満の優性スクリーニングに成功し
た。家系の樹立から遺伝子変異の同定まで、実質的に２年程度であった。見出した遺伝子変
異は Sim1 と Mc4r であり、どちらも機能欠失型の変異である。過去の報告から Sim1 と
Mc4r とも haploinsufficiency によって肥満を呈することが知られており、今回見出した遺伝
子変異が肥満の原因になると考えられる。見出された遺伝子はいずれもエネルギー代謝にお
いて重要な役割を持つことが知られている遺伝子である。エネルギー代謝に関与する多くの
遺伝子がすでに知られていることから、新たなエネルギー代謝制御遺伝子を見つけることは
かなり難しそうである。 
結    論： 
C57BL/6 サブストレイン、体外受精、全エクソームシーケンスを組み合わせたフォワード・
ジェネティクス研究は感度が良く、家系の維持が安定している。肥満以外の表現型への応用
が可能である。 
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Abstract 
 
Purpose: 
In order to identify a gene essential for a defined biological phenomena, forward genetic  
strategy acts as one of the most influential approaches and enables us to understand the 
genetic basis of human biology and disease, when applied in model animals such as fruit fly 
and  mouse. The forward genetic strategy that is a phenotype-driven and hypothesis-free 
approach, will help to identify novel genes which may play a crucial role in the target 
behaviors. The forward genetic study demonstrates its strength in research areas in which a 
gene-targeting approach would not work because of the redundant and compensatory 
regulation of target phenotypes. Although the forward genetics is usually a time-consuming 
project, which usually takes more than five years from the phenotype screening to identify a 
candidate gene mutation, the recent advance in DNA sequencing technology have been sped 
up the process from the linkage analysis to identified candidate mutations.  
In order to identify novel genes regulating sleep/wakefulness, our laboratory has been 
undertaken a large-scale forward genetic screen of sleep abnormalities. Through the 
screening, we found several mutagenized mice that showed severe obesity. Since we were 
looking for dominant phenotypes, severe obesity of these mice could be inheritable in a 
dominant manner.  Although there had been no successful dominant screening for obesity, we 
hypothesized that two major reasons of no success are: 1) the quantitative trait locus between 
the mutagenized mice strain and counter strain may make the effect of mutations obscure, 2)  
mice with severe obesity usually exhibit a very low fertility so that it is very difficult to 
establish and keep dominantly obese pedigrees. One of the two major characteristics of our 
forward genetic scheme is the use of C57BL/6 (B6) substrains, B6J and B6N for the 
mutagenized and counterstrains. B6J and B6N are very similar in metabolic phenotypes 
consistent with a close phylogenetic distance, which is suitable to detect the metabolic effect 
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of mutations reliably. Another characteristic is the routine use of in vitro fertilization, which 
enables us to establish and keep pedigrees of mice that show low fertility in natural breeding. 
Thus, our dominant screening scheme may overcome the issues that led to abort dominant 
screening of obesity in the past studies.  
The purpose of the current study was two-fold; i) to evaluate the efficiency and 
reproducibility of our new forward genetic scheme by conducting the dominant screening of 
obesity, 2) to identify the gene mutation that causes obesity in a dominant inheritance. If the 
identified gene is a novel player in the homeostasis of energy metabolism, the mutant mice 
may afford a new genetic model for the human metabolic syndrome, as well as new insights 
into the pathophysiology of obesity. 
Material and methods: 
In parallel with examining the sleep/wakefulness abnormalities we have dominantly screened 
the same ENU mutagenized mice for obesity using C57BL/6 substrains. Initially, 
intraperitoneal injection of ENU was given to the wild-type male C57BL/6J mice at 8-10 
weeks of age. After a sterile period (10-11 weeks) the injected males were crossed (IVF) with 
C57BL/6J or C57BL/6N wild-type female to produce G1/F1 progeny. Phenotypic screens of 
G1/F1 progeny were routinely carried out. The phenodeviant F1 male mice were again mated 
(IVF) with C57BL/6N wild-type females to produce N2 progeny. The N2 progeny was then 
subjected to the inheritance testing of obesity and linkage analysis. Further, by whole exome 
sequencing as well as direct sequencing the mutation of candidate gene of the established 
pedigrees was identified. Subsequently, assay of transcriptional activity, metabolic 
characterization and quantitation of hypothalamic gene expression was performed to observe 
the role of candidate gene mutation. 
 
 viii 
 
Result: 
In this dominant screening, total thirteen G1/F1 obese male were selected to establish obesity 
pedigrees. Among them, we have established two obese pedigrees. Linkage analysis of one 
obese pedigree showed a single LOD score peak on the chromosome 18. In this case, we 
found a single nucleotide substitution of Mc4r gene in obese mutant mice, which results in a 
premature stop codon in the first transmembrane domain of Mc4r protein. Linkage analysis of 
another obese pedigree exhibited a single peak of LOD score on chromosome 10. Through 
the whole exome sequencing and direct sequencing, we found a single nucleotide substitution 
of the Sim1 gene, which causes a nonsynonymous change of a well-conserved residue in the 
PAS A domain, crucial for functional dimer formation with Arnt2. As predicted, We further 
confirmed using luciferase assay that the mutant Sim1 protein lacks transcriptional activity. 
Therefore, through the metabolic assay both of the obese pedigrees showed a strong 
correlation with the human and mice having heterozygous in Mc4r or Sim1 gene. Because 
both Sim1 and Mc4r are expressed in the hypothalamus, a regulatory center of feeding and 
energy metabolism, we examined hypothalamic gene expression of Sim1 mutant and Mc4r 
mutant mice, and further compared with those of high-fat diet-induced obesity (DIO) mice. 
All three obese mice showed decrease in Avp mRNA. Both Sim1 mutant and DIO mice had a 
lower level of Agrp mRNA. The Sim1 mutant mice exhibited decreased level of Orexin, 
Oxytocin and Trh1 mRNAs Whereas, DIO mice showed a decrease in Pacap and Ghrh 
mRNAs. These findings confirm that the crucial roles of Sim1 and Mc4r in maintaining 
energy homeostasis and substantiate the sensitivity of our forward genetic screening as well.  
Discussion: 
Through the dominant screening of obesity using B6 substrains, we have established two 
obese pedigrees. One pedigree showed mutation in Mc4r gene and another showed mutation 
in Sim1 gene. To the best of our knowledge, this is the first successful dominant screening of 
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obesity. One of the main reasons of the successful dominant screening may be the use of B6 
substring as the mutagenized and counter strains. Since B6J and B6N have the almost same 
genetic background and there is no significant QTL between them regarding body weight, the 
phenotypic change exhibited a very well correlation with the presence of mutation in the 
Mc4r and Sim1. 
Since obesity strongly affects the fertility, it is very difficult to produce the next generation 
by natural mating between the obese mice. Thus, in vitro fertilization is required to obtain 
offspring  of obese mice. After the heritable test of obesity phenotype, a linkage analysis and 
subsequent whole exome sequencing enabled us to identify the candidate gene mutations in 
the obese mice. Further, a direct sequencing confirms the presence of mutations in the Mc4r 
and Sim1 genes in Obese-10 pedigree and Obese-13 pedigree, respectively.  
The founders of the Obese-10 and Obese-13 pedigrees were the most obese mice among all 
5000 G1/F1 males. Thus, a strong phenotype that negates the fluctuation of body weight due 
to other correlated factors is necessary for the successful dominant screening for obesity. 
Therefore, it would be very difficult to succeed in dominant screening if the obesity caused by 
mild or moderate effect of genetic mutation or by the strong effect of other correlated factors. 
The metabolic phenotypes of Obese-10 and Obese-13 pedigrees were consistent with those of 
heterozygous Mc4r or Sim1 deficient mice, respectively. Further, the decreased 
transcriptional activity of SIM1(136K) protein found with a luciferase assay demonstrates 
that the loss of function of SIM1 protein may render Obese-13 mutant mice overweight.  
Finally, the quantitation of hypothalamic gene expressions of these obese mutant pedigrees 
along with diet-induced obesity mice exhibits distinct gene expression patterns in the 
hypothalamus. 
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Conclusion: 
This dominant screening of obesity in ENU-mutagenized mice successfully established two 
obese pedigrees and identified the candidate genes. Thus, this dominant screening strategy 
using C57BL/6 substrains would be a very applicable method in obesity screening or in any 
research area to identify the candidate gene that affects a variety of behavioral and metabolic 
phenotypes. 
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Chapter 1. 
Introduction and review of literature 
 
1.1. Factors affecting the efficiency of forward genetic screening using mice 
1.1.1. General introduction of screening of randomly mutagenized mice 
Forward genetics:  
The term forward genetic encompasses several means of identifying the genotype that is 
responsible for a phenotype. Forward genetic comprises of assortment a biological process, 
produces mutant population, screen for mutant with a preferred phenotype, map and clone the 
gene responsible for the phenotype1. Forward genetic approach starts with an ask on behalf of 
particular biological characteristic disease (e.g. obesity), and to know about the responsible 
gene that supports the produced occurrence1 and is very useful in identifying molecular maps 
of the pathways controlling basic biological functions of a given trait2. To understand the 
genetic basis of human biology and disease using any model animals such as fruit fly and 
mice, the forward genetic approach is acting as an one of the most influential methods in the 
mordern era1.  
The forward genetic is opposite of reverse genetics. The reverse genetics contribute to 
analyze the phenotype of an organism following the disruption of a known gene. The 
strategies of reverse genetic involve in direct manipulation of specific genes, either by 
targeting mutagenesis or transgenesis. This strategy is driven by the manipulation of DNA. It 
also proceeds from a simple molecular change to the complex effects of that change by 
investigating the functional consequences of a specific mutation in the context of the whole 
organism2. Both of the strategies are complementary and extensively used in all model 
organisms. 
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History of forward genetic approach: 
In earlier genetic studies, the house mouse Mus musculus was originally used3. A variety of 
visible phenotypes such as obesity4 observed in the house mouse were found to be caused by 
spontaneous mutations. But, the use of spontaneous mutations to examine the function of 
genes had some limitations, due to low spontaneous mutation rate in mouse germ cells (5x10-
6 per locus)5.  In 1927, the X-rays were first used to induce heritable mutations  capability to 
induce mutations at a rate 20 times higher (13 × 10-5 to 50 ×10-5) than that of spontaneous 
mutation6. The X-ray mutagenesis causes a wide variety of chromosomal rearrangements, 
such as deletions, inversion, translocations, that affect multiple genes. After it several 
chemicals such as procarbazine, triethylenemlamine, chlorambucil etc. have been used for 
their ability to generate mutagenesis with a greater frequency in germ cells in several model 
organisms, but they also exhibit some problems of genetic lesions associated with early or 
late spermatogensis6,7. It soon became clear that physical or chemical means of inducing 
mutations must be necessary in order to examine the function of all of the genes in the mouse 
genome more quickly. In 1979, Russell’s group at the Oakridge National Laboratory first 
used ENU in the mouse to induce mutation and found that ENU is the most powerful 
mutagen of spermatogonia in mice8. The rate of inducing mutations by the ENU was at a 
frequency of up to 150 × 10-5 per locus6,9,10. These findings, considered as a milestone in 
mouse genetics, for the generation of new mouse mutants. In the 1980s, geneticists began to 
embrace the technique of ENU mutagenesis in a large scale, using ENU in a region-specific 
screen11. Therefore, several research groups are engaged in genetic screens using ENU 
mutagenesis with a high proficiency in the recent era. By the use of forward genetic approach 
the recent advances in DNA sequencing technology have been sped up in identifying disease 
causing mutations in mutagenized mice1. 
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N-ethyl-N-nitrosourea (ENU) mutagenesis: 
The synthetic alkylating chemical agent N-ethyl-N-nitrosourea (ENU)12 is toxic and 
carcinogenic to the cells, potent mutagen, and primarily affects spermatogonial stem cells. 
The most powerful mutagenic effect of ENU is widely used for mutagenesis in mice. It does 
not require any metabolic processing for its activation13. ENU induces random point 
mutations in the spermatogonial stem cells at a frequency of ~150x10-5 per locus in mice8. 
ENU transfers its ethyl group to oxygen and nitrogen reactive sites of the nucleotides14. The 
transferred ethyl group constitutes a DNA adduct that results in heritable mutations during 
cell proliferation and DNA replication15. During replication ENU causes mispairing and base 
pair substitutions in DNA10,16. Most of the ENU-induced mutations are single base pair 
substitutions that cause missense errors, as well as the other mutations like  splice site errors, 
and nonsense mutations17. Approximately, 70% to 85% of all ENU-induced nucleotide 
substitutions are assessed to be either A-T to T-A transversions or A-T to G-C 
transitions14,18,19. On the other hand, the G-C to C-G transversion event is rarely seen20. Some 
amino acid changes will be under represented due to the low frequency of G-C to C-G 
transversions. However, the evidence from the prevalent successful use of ENU mutagenesis 
that these preferences have so far limit the successful identification of new mutant models 
over the past three decades21. ENU is usually administered by intraperitoneal injections to 
adult male mice. It has largely been elucidated that the doses and injection regimes of ENU 
play an important role in the most efficient induction of heritable mutations in different 
strains of mice22–24. 
A typical treatment schedule might comprise at the most common dosage (two/three weekly 
i.p. injection at 80-100 mg/kg) for an adult male mouse. However, the optimum dose and 
regime vary according to the strain of mouse being used25. Generally, ENU creates an 
average of 60 coding changes per sperm, which would correspond to approximately one 
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mutation per 700,000 bp of the target DNA sequence19,26. As ENU is toxic and carcinogenic, 
so an increase in dose may result in a higher mutation load but it may cause a reduction in the 
viability of the mouse reproductivity23,25. 
Dominant vs recessive screen:  
The phenotype-driven approach of forward genetics is considered as unbiased, because it 
makes no assumptions with regard to the genetic basis or cause of a particular disease. In the 
phenotype-driven screens of the mouse, the chemical mutagen ethyl nitrosourea (ENU) has 
been used as a principle mutagenesis strategy. The success of screening depends on the 
optimal selection of a number of considerations in ENU mutagenesis, such as breeding 
strategy, ENU dose, mouse strain and method of phenotypic detection, which are often 
dictated by the phenotype or disease that one wishes to examine27. One of the first choices a 
researcher must make is whether to perform a dominant or recessive screen. In a dominant 
screen, a phenotype must be detected when only one copy of the mutant gene is present; 
whereas, a recessive screen allows for the identification of genetic mutations that are 
inherited in a recessive fashion. The decision of whether to perform a dominant or recessive 
screen is frequently decided by the type of disease one wishes to examine, but the advantages 
and disadvantages of each type of screen must also be considered27. 
In the dominant screening of ENU-mutagenesis strategy, the chemical mutagen 
ethylnitrosourea (ENU) is generally administered to male (G0 male), where the mutagen ENU 
acts most effectively on spermatogonial stem cells and generate mutation. This mutagenized 
male (G0 male) is then bred with wild-type female and transmits the ENU-induced mutations 
to the G1 progeny (the counter strain is same as G0 males) or F1 progeny (the counter strain 
is different than G0 males) (Fig. 3a). In order to get a large number of candidate mutants, the 
maximum number of G1/F1 progeny is necessarily produced and the primary phenotype 
screen is conducted the G1/F1 population as thoroughly as possible. The detection rate of 
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mutants depends upon the number, type and accuracy of the phenotypic parameters, 
environmental and genetic background and observation period28. Then the linkage analysis or 
subsequent mapping is performed using N2 progeny. Dominant screens have a simple 
breeding scheme requiring a small number of animals than the recessive screening27. 
A recessive screen comprises of a three-generation breeding scheme to get homozygous 
mutations in a proportion of the resultant G3 offspring, and can be conducted in at least two 
ways. G0 males are bred to wild-type females to produce G1 progeny and then G1 males are 
crossed to wild-type females to produce G2 progeny. G2 females can either be crossed to 
other G2 males from the same pedigree (intercross) or they can be crossed to their fathers 
(backcross) (Fig. 1). In either case G3 progeny is produced. G3 animals are then screened  for 
a particular phenotype5,27. In a recessive backcross, some litters will have 25% of pups 
affected, whereas other litters will have no affected animals. Recessive screens, however, are 
complex, require an intensive animal caretaking and large breeding facilities when compared 
to dominant screens5,27. 
 
Figure 1. Recessive screening of ENU-mutagenized mice27 
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1.1.2. Linkage analysis and mouse strain 
The term linkage can be elucidated as the tendency for genes and the genetic markers to be 
inherited collectively due to their location near one another on the same chromosome. 
Linkage analysis is a great tool to recognize the chromosomal location of disease genes. It is 
a study to aim at establishing linkage between genes based on the observation that reside 
physically close on a chromosome and linked during meiosis29. Linkage analysis exerts the 
mapping of the chromosomal location of disease by testing the co-segregation of marker 
alleles with the disease phenotypes. It is a classic method to explore the genetic determinants 
of disease30. Linkage mapping, also named as positional cloning, which involved in 
systematic scanning of the entire DNA contents of various family members affected by the 
disorder using frequently spaced, polymorphic DNA segments whose exact position is 
known31. From the beginnings as a model organism for research, mouse plays the s excellent 
role in genetic studies. Mice have a short generation time, has a well-characterized genome, 
which is similar to humans, deliver large progenies and breed year round and easy to 
maintain5. Compared to the other mammalian species mouse has the ability to tolerate 
inbreeding well. Due to the polymorphic variations, inbred mouse strains provide a defined 
genetic background reducing variability27. The mouse genome was the first mammalian 
genome to be sequenced after the human genome in 200032 and almost about ninety-nine 
percent of genome identity and gene functions are observed between mice and humans33. For 
the first time, the mouse genome to be sequenced was a mix of different strains of mouse 
(129S1/SvImJ, 129X1/SvJ, A/J, C57BL/6 and DBA/2J), while in 2002, the C57Bl/6J mouse 
strain was fully sequenced33. The mouse genome is relatively easy to manipulate and the 
pathogenic consequences of genetic mutations in mouse is parallel to the humans pathogenic 
consequences27. Mouse models of human disease, thus allow for in-depth biological studies 
that are not possible in humans5.  
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The mating mouse strain plays an important role to generate linkage in a QTLs. Because, 
linkage analysis can be carried out between a single marker locus and a putative disease locus 
or across a set of markers consisting of a small number of markers or even all markers on a 
given chromosome. The parent mice must be heterozygous at each of two loci to be 
informative for linkage otherwise, an insufficient information will be produced to distinguish 
recombinant from non-recombinant events  in offspring34. The different characteristic effects 
of different QTLs between the mutagenized and backcross strains may confound the mapping 
of the mutant locus and sometimes lower the statistical control in detecting mutant locus 
based on LOD score35. Generally, a mutagenized strain and a counter strain are identical in 
their genomic DNA except for 4-6 single nucleotide polymorphisms per chromosome. But, 
the availability of polymorphic marker is necessary in a linkage analysis. Recently a number 
of polymorphic markers such as microsatellites and SNPs between inbred mouse strains are 
available. Generally, the ENU-treated C57BL/6J (B6J) mice used to cross with DBA/2J36, 
BALB/c37 or C3H/He38,39 mice. These inbred strains possess more than 5,000,000 genetic 
variations relative to the B6J strain40. On the other hand, the C57BL/6N (B6N) strain, a  B6 
substrain, which has  approximately 17,000 genetic variants relative to B6J mice with only 
108 non-synonymous coding changes41. The list of available SNPs (Single nucleotide 
polymorphisms) between the C57BL/6J and C57BL/6N mice strains helps to use these mice 
strains in forward genetic screening. Thus, a successful quantitative trait loci (QTLs) between 
the screening strain treated with (ENU), and the counter strain used for the backcross is 
somehow depends upon the uses of mating mouse strain. However, each inbred mouse strain 
exhibits a characteristic profile of body weight regulation and energy metabolism in a same 
feeding condition42,43 under the influence of QTLs44.  
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1.1.3. Fertility and in vitro fertilization (IVF) 
Fertility is the natural capability to produce progeny. Human fertility is affected by various 
factors. By reducing the spermatogenesis obesity strongly and adversely affect the male 
fertility. The frequency of obesity is rapidly rising in worldwide which  affects both women 
and men, where, male obesity is an issue of serious concern in case of infertility45. The 
prevalence of obesity has also raised tremendously in the women of reproductive age. Female 
obesity affects the ovulation. The excessive fat delays time to pregnancy (TTP) causing 
poorer embryo development, and in effects on the endometrium. The obesity epidemic has 
been accompanied by a potential rise in male infertility, which has been endorsed to 
hormonal disturbances and compromised semen parameters46.  
Besides, in vitro fertilization is a kind of assisted reproductive technology through which the 
fertilization process is done by manually combining of sperm and egg in the laboratory dish 
and the embryo is then transferred to the uterus. Recently, in vitro fertilization is one of the 
most extensively used interventions for the condition of infertility47. In parallel with the 
human, a strong relationship between obesity and infertility was found in mice also48. In that 
case the production of progeny using natural mating between obese male and female is 
difficult. Instead, a routine use of in vitro fertilization is favorable to generate the next 
generation in case of obesity phenotype. 
1.1.4. Candidate gene approach vs whole exome sequencing 
The candidate gene approach is an important tool for studying complex genetic diseases. It is 
composed of the following aspects to explore genetic influences on a complex trait. (1) 
Preparation of hypotheses and identification of candidate genes having a role in the etiology 
of the disease. (2) Detection of genetic variants with functional changes or non-functional 
variants, which is linked disequilibrium with positive polymorphisms. (3) Genotype the 
variants in a population. (4) Assessment of the correlation between those variables and the 
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phenotypes49. The correlations between genetic variants and trait differences can be examined 
by the genetic association studies on a population scale50. To identify the genes responsible 
for mendelian diseases the linkage analyses and positional cloning have been successfully 
used in the past two decades. However, linkage study could not show a successful result in 
identifying diseases related gene in complex diseases characterized by heterozygous 
phenotypes, a variety of biological pathways or functional variety of genes with a small 
contribution. Whereas, the candidate gene approach exerts its effects as a promising 
alternative approach49. In the candidate gene approach, after choosing a candidate gene and 
suitable polymorphism, the investigators commonly test the role of the gene in a sample of 
randomly chosen subjects of the disease in comparison with the control group of the litter 
mates51. A combination of candidate gene approach and linkage mapping plays as a most 
applicable method of identifying disease genes to date. The candidate gene approach exerts 
firm advantages over positional cloning or linkage mapping and is applicable in quick 
determination of genetic variants with the disorder as well as in identifying the genes having 
modest effect31. 
Whole exome sequencing is a method used for sequencing of all the expressed genes in 
a genome or exome. It is a widely used targeted high-throughput DNA sequencing 
technology, which encodes and sequences the protein coding portion of DNA (known 
as exons)52. It can identify the genetic variation with a high effectiveness, but less costs in 
comparing to the  whole-genome sequencing. It is widely applicable in identifying 
the Mendelian and other common diseases associated with genetic variations53. In order to 
sequence of massive numbers of different DNA strands at once a large number of  equivalent 
DNA-sequencing systems are available. These technologies play a major role  in  developing 
of our understandings in medical genetics, hasten health-improvement projects, and guiding 
to a fully understood  personalized medicine in the near future54. To the complement of the 
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other sequencing methods, the whole-exome sequencing is now progressively used to identify 
novel genes by comparing exomes and also to find mutations in genes already known to 
cause disease from patients with similar features. The whole-exome sequencing is  a powerful 
application of the next-generation technology for determining the variations of all exons or 
coding regions,  of known genes. It provides exposure of more than 95% of the exons, that 
contains 85% of disease-causing mutations in many disease-predisposing SNPs throughout 
the genome. The whole-exome sequencing  has been used to distinguish more than 150 
genes, and this statistics is rising rapidly54.   
1.2. Forward genetic screening for obesity 
1.2.1. General introduction of obesity 
Obesity:  
Obesity can be defined as the increased fat mass to an amount that is harmful to health. 
According to world health organization (WHO) the overweight as well as obesity is defined 
as abnormal or excessive fat accumulation that provides a threat to an individual’s health. 
Since 1980 worldwide obesity has more than doubled. According to WHO about 42 million 
children under the age of 5 were overweight or obese in 2013. Besides, more than 1.9 billion 
adults (18 years and older) were overweight, among them more than 600 million were obese 
in 2014.  Statistically, about 39% of adults were overweight and 13% were obese in the year 
of 2014. Overweight and obesity acts as a major risk factor for a number of chronic diseases. 
In addition to the developing countries, overweight and obesity also considerably on the rise 
in middle income as well as low income countries, particularly in urban settings. 
(http://www.who.int/mediacentre/factsheets/fs311/en/). 
Prevalence of obesity:  
The obesity prevalence has increased significantly in a single generation among adults and 
especially, children.  The prevalence of obesity has been increased drastically, with diverse 
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regional patterns and distinct variations throughout countries in the levels and trends in 
overweight and obesity in the past three decades55. A high prevalence affects nearly all rich 
countries and is rapidly increasing among more rich populations of poorer countries. The 
burdens of ill health put greater burdens on families and social support services, on health 
services and lessen the output of national economies56. In 2010, overweight and obesity were 
estimated worldwide to cause 4% of disability-adjusted life-year, 4% of years of life lost and 
3·4 million deaths57. Worldwide, the prevalence of overweight and obesity combined rose by 
47·1% for children and 27·5% for adults between 1980 and 2013. The number of overweight 
and obese individuals amplified from 857 million in 1980, to 2·1 billion in 201355. 
Consequences of obesity: 
Obesity causes and intensify many health consequences resulting from the extra fat mass or  
increased free fatty acids and enlarged fat cells secreted peptides. The diseases obstructive 
sleep apnea58 and osteoarthritis of large and small joints59 are associated with increased fat 
mass. The enlarged fat cells secreted adipocytokines are correlated with type 2 diabetes 
mellitus60,61, cholelithiasis62, nonalcoholic fatty liver disease and nonalcoholic 
steatohepatitis63, coronary heart disease64, hypertension 65 and sometimes certain forms of 
cancer66,67. Obesity acts as a cardiovascular risk factor for children, which is predictive as of 
adult cardiac risk and even causes premature death68. Childhood obesity is broadly correlated 
with heart disease,  surpassing undernutrition and infectious diseases69. A number of 
population studies have shown considerable evidence that obesity shortens the duration of 
life70–74. 
Causes of obesity:  
Several factors are responsible to cause obesity. The excessive food or energy intake and a 
lack of physical activity play a major role to cause obesity75. The genetics, psychiatric illness 
or medical reasons also act as a great reason to cause obesity76. Besides, the easily accessible 
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and palatable diet, increased reliance on cars, and mechanized manufacturing increasing rates 
of obesity at a public level77–79. In addition the following possible matters also contribute to 
the recent increase of obesity: endocrine disruptors, insufficient sleep, decreased variability in 
ambient temperature,  increased use of medications that can cause weight gain, smoking, 
proportional increases in ethnic and age groups that tend to be heavier, epigenetic risk factors, 
pregnancy at a later age, natural selection for higher BMI, and assortative mating leading to 
increase concentration of obesity risk factors80. Further, there also some other factors 
supporting the influence of these mechanisms on the increased prevalence of obesity. 
Genetic determinants of obesity:  
Among the various potential causes for obesity the certain genetic conditions play a major 
role to cause obesity. The genome-wide association studies already have been identified a 
number of genetic variants, those are associated with obesity81. Molecular genetic studies has 
been identified a few numbers of candidate genes for human obesity. Mutation of these 
candidate genes develops the excessive body weight, but the causal mutations are rare and 
unable to expose the current obesity epidemic. Each of the single gene variant has only a 
minute influence on the body weight, but the genetic propensity to the common obesity is 
most likely has a polygenic basis82. Besides of the common variants, FTO and MC4R, new 
loci, such as GNPDA2T, KCTD15, MEM18, MTCH2, NEGR1 and SH2B1 have been 
identified81. The (GWAS) study can offer the new opportunities for the genetic study of the 
complex  obesity disease. The genetic determinants strongly influence  in people with severe 
and early-onset obesity as well as some unfavorable clinical consequences (Fig. 2)83. 
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Figure 2. Genetics of obesity83 
1.2.2. History of forward genetic screening for obesity   
In 1949, a strain of obese offspring was found at the Jackson Laboratory by the study of a 
non-obese mouse colony. This result suggests for the presence of a mutation (ob/ob)  in a 
hormone regulating hunger and energy expenditure in the obese mice4. In the 1960s, at the 
Jackson Laboratory a second mutation (db/db) causing obesity as a similar phenotype was 
identified, exhibiting diabetes and obesity84. After the seminal discovery of leptin  in (ob/ob) 
mice in 1994 and leptin receptor in db/db mice in 1995 through the forward genetic studies 
on recessive mice85, the application of forward genetic approach has been  widely used to 
identify the molecular network of gene  associated with obesity and energy homeostasis. 
Subsequently, the forward genetic study using ENU mutagenized mice, have found the 
obesity-causing mutations in the Mc4r39,86, leptin37 and leptin receptor87 genes through the 
recessive inheritance. However, there was no evidence of finding dominant heritable traits 
related to obesity using a successful dominant screening of forward genetic approach. 
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1.3. Leptin and hypothalamic neuron network 
Leptin:  
Leptin is a 167-amino-acid peptide which is generated from adipose tissue. The level of 
leptin in the systemic circulation is directly proportional to the amount of body fat and 
fluctuate within the changes of caloric intake, thereby signaling the quantity of stored 
energy88. Generally, leptin exerts its effect centrally by interacting with various neuronal 
pathways particularly in the hypothalamus of brain, through orexigenic and anorexigenic 
neuropeptides and regulate food intake. In the arcuate nucleus of the hypothalamus, leptin 
activates  pro-opiomelanocortin (Pomc) and cocaine- and amphetamine-regulated88 transcript 
(CART), to suppress appetite, and inhibits Agouti-related peptide (Agrp) and Neuropeptide 
Y(Npy), both of which are generally stimulate appetite89,90. In the lateral hypothalamus area, 
leptin decreases the expression of the orexigenic peptides Melanin-concentrating hormone 
(Mch)91 and Orexin92. Besides, of controlling  the energy intake through the central regulation 
of appetite and satiety, leptin also regulates energy expenditure possibly through the 
suppression of Mch93. On the other hand, mutations or deficiency in the gene encoding the 
leptin receptor exhibit severe early-onset obesity associated with hyperphagia94,95 and 
administration of leptin  reduces the obesity in leptin deficient mice96 and in leptin deficient 
humans97. 
Insulin:  
Insulin is a kind of peptide hormone that secrets from the pancreatic beta cells. Insulin secrets 
for short term depending upon the blood glucose level on the other hand, in response to the 
adiposity level, insulin secrets for a long tern98. Insulin has a strong impact in regulating 
glucose homeostasis and lipid metabolism and central administration of insulin inhibits food 
intake and decreases body weight99. The action of insulin is mediated by the insulin receptor 
(InsR), which is expressed in several areas of the CNS including the hypothalamus. Insulin 
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strongly expressed in Pomc and Agrp neurons of the ARC and contributes in the regulation of 
glucose homeostasis, food intake and body weight89,100–102. In the hypothalamus insulin 
regulates the AMPK signaling pathway  to energy balance103. The brain-specific deletion of 
Insulin receptor in mice exhibited  diet sensitive obesity associated with increased food 
intake104 and central administration of insulin regulates feeding behavior. The selective 
ablation of insulin receptor  in Agrp or Pomc neurons does not show any effect on food intake 
or body weight, but, the transgenic deletions of insulin receptor in Agrp or Pomc neurons 
have an impact on glucose metabolism representing the importance of insulin action in the 
regulation of glucose homeostasis on the Agrp and Pomc neurons101. 
Proopiomelanocortin (Pomc): 
The Pomc neurons are found in the arcuate nucleus of the hypothalamus and  nucleus tractus 
solitarius of the brain stem and involve in the regulation of food intake as well as energy 
expenditure105. In the hypothalamic arcuate nucleus, leptin and insulin acts in activating 
Pomc neurons89,90,106. The activated Pomc neuron releases α-MSH, which binds with Mc4r 
gene and decrease food intake and increase energy expenditure107,108. Activation of 
hypothalamic nicotinic acetylcholine receptors (alpha-3 and beta-4) leads to activates Pomc 
neurons. The activated Pomc neurons subsequently activate the melanocortin-4 receptors and 
decreases food intake in mice109. On the other hand, Pomc deficiency exhibits early-onset 
obesity  associated with hyperphagia due to the lack of melanocortin-4 receptors 
activation110. 
Agouti-related peptide (Agrp): 
The neuropeptide Agrp is synthesized in NeuropeptideY containing Agrp/Npy neuron located 
in the ventromedial part of the arcuate nucleus in the hypothalamus111. Agrp co-expresses 
with Neuropeptide Y and increases appetite as well as decreases energy expenditure and  
metabolism112,113. Intracerebroventricularly (ICV) administration or transgenically expression 
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of Agrp causes hyperphagia. Thus, the activated Agrp promotes food intake and positive 
energy balance by antagonizing Mc4r genes located in PVN112,114,115. Moreover, insulin and 
leptin inhibit Agrp expression and regulates food intake and energy expenditure106. Since 
Agrp neurons are inhibited by insulin and leptin thus, they are activated by the decline of 
insulin and leptin signalings116. The hypothalamic Agrp neurons also express the 
neurotransmitter GABA, Npy as well as many other molecules, having vital functions in a 
physiologic circuit117. 
NeuropeptideY (Npy): 
NeuropeptideY (Npy) is an amino acid peptide that produced in various parts of the brain, 
especially in the hypothalamic arcuate nucleus118. Npy exerts its functions through the five 
highly conserved NeuropeptideY receptors. It is one of the most potent orexigenic 
neuropeptides. Npy coexpress with Agrp an endogenous antagonist of the Mc4r to exert 
orexigenic effects in increasing food intake as well as  storage of energy as fat112,115. 
However, Npy is inhibited by insulin and leptin in the hypothalamus and decrease food 
intake119,120. As the Npy neurons are inhibited by insulin and leptin thus, the decline of insulin 
and leptin signaling demonstrates to activate Npy to exert its orexigenic action116. Injection of 
Npy into the hypothalamus of rats increase food intake and decreases energy expenditure121. 
Therefore, Npy on repeated administration leads to obesity121,122. On the other hand, genetic 
knockout of Npy reduces hyperphagia and obesity in ob/ob mice123. 
Melanin concentrating hormone (Mch): 
Mch is an orexigenic hypothalamic peptide originated from the pituitary gland.  Though Mch 
expressing neurons are mainly located in the lateral hypothalamus and zona incerta but, the 
neurons project widely throughout the brain124,125. In the regulation of food intake  as well as  
energy homeostasis Mch plays an important role. Mch deficient mice exhibit a characteristics 
of  hypophagia and lean body weight with increased metabolic activity126–128. Whereas, 
 17 
 
transgenic mice which overexpress Mch shows a characteristics of obesity and resistance to 
insulin129. The Mch overexpression in hypothalamus also found in the leptin deficient 
ob/ob mice exhibits characteristics of  hyperphagia  and centrally administration of Mch 
promotes food intake and weight gain130. 
Orexin/hypocretin neuropeptide: 
Orexin is a neuropeptide (prepro-orexin mRNA) found in the neurons within and around the 
lateral and posterior hypothalamus of the brain131. In parallel with the regulation of  arousal 
and wakefulness Orexin also regulates appetite behavior. The central administration of 
Orexin peptides in rats exhibit a positive stimulation of food consumption131. The orexigenic 
peptides not only act within hypothalamic centers, but are also capable to regulate food intake 
through their activities at extra-hypothalamic centers, such as in the regions of  brain’s 
endogenous reward circuitry132,133. Orexin enhances the hunger for food, and other functions 
those correlated with the enhancement hunger production. By  suppressing the inhibitory 
feedback Orexin also acts to increase meal size134. 
Oxytocin neuropeptide: 
Oxytocin is a type of peptide hormone generally produced from the parvocellular 
paraventricular nucleus (pPVN) as well as magnocellular neurons in both the supraoptic 
nucleus (SON) and PVN. Oxytoxin also produced in the anterior hypothalamus, medial 
amygdala, medial preoptic area, bed nucleus of the stria terminalis (BNST) and in the 
periphery135–137. In the neural circuits Oxytocin plays a major role in appetite along with 
social behavior, anxiety or stress138,139 as well as in the regulation of  body weight140,141. 
Animal studies revealed that Oxytocin control the body weight142,143 by inhibiting the 
appetite, particularly for carbohydrates and sugar140,144. The diet induced obese mice show 
functional abnormalities in Oxytocin systems. Injections of  Oxytocin receptor antagonist in 
wild-type mice increase  the consumption of sucrose over fat145. Whereas, Oxytocin receptor 
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deficient animals develop late onset obesity146,147 and increased consumption of sweet 
solutions in compared with wild-type animals148 and the administration of Oxytocin exhibit 
weight loss149. 
Growth hormone releasing hormone (Ghrh): 
Ghrh is a kind of peptide hormone, which  produced in the arcuate nucleus of 
the hypothalamus150. The neurosecretory nerve terminals of arcuate neurons, releases Ghrh 
that carried out to the anterior pituitary gland by the hypothalamo-hypophyseal portal system. 
In the anterior pituitary gland it stimulates the growth hormone-releasing hormone receptor 
promotes for Growth hormone (Gh) secretion151,152. 
Thyrotropin releasing hormone (Trh): 
Trh is a hormone generally produced in the paraventricular nucleus of the hypothalamus and 
acts as a key regulator of  hypothalamic-pituitary-thyroid axis153. Trh is also found in many 
other brain loci outside of the hypothalamus as well as in various nonneuronal tissues such as 
heart, reproductive organs and gastrointestinal tract154. Trh mainly regulates the thyroid-
stimulating hormone secretion for the maintenance of thyroid hormone homeostasis155. 
Besides, Trh also regulates the release of several other hormones such as Insulin, 
Vasopressin, Growth hormone and Prolactin156,157. Trh plays an important role in the CNS in 
the regulation of energy homeostasis153. Central administration of Trh or agonist of Trh 
exhibits a significant reduction of  food intake in models of stress-induced feeding, hungry 
rats or in normal rodents158–163. Subcutaneously administration of Trh in rat also exhibits 
increases water intake and body temperature, but decreases food intake164. Trh indirectly 
affects in energy homeostasis165 and in upregulation of locomotor activity166,167. Trh inhibits 
Mch neurons by synaptic inhibition of local GABA neurons and reduces the Trh mediated 
food intake168. 
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Arginine vasopressin (Avp): 
The Arginine vasopressin is a neuropeptide hormone found in the paraventricular nucleus 
(PVN) of the hypothalamus  and in the supraoptic nucleus (SON) of the brain169. The primary 
functions of Avp are to regulate the retention of water in the body and high concentrations 
Avp raise  blood pressure by constriction of blood vessels170,171. Peripheral administration of 
Arginine vasopressin in goat reduces cumulative food intake in a dose-dependent manner. 
This hypophagic effect of Avp was reversed by both a V1-receptor antagonist and an alpha-
adrenergic antagonist. Avp also exhibits stress-induced anorexia172. 
Pituitary adenylate cyclase activating polypeptide (Pacap): 
Pituitary adenylate cyclase activating polypeptide (Pacap)  is a hypophysiotropic hormone 
involved in adenohypophyseal hormone release173 as well as a neuropeptide expresses in the 
central and peripheral nervous systems174 and numerous tissues in vertebrates175. In the 
neuroendocrine control of food intake Pacap exerts an important role. Besides, it exhibits an 
anorexigenic effect on the regulation of satiety. Intracerebroventricular (ICV) administration 
of Pacap  decrease food intake in mouse176, rats177,178, Chick179 and goldfish180. The results 
suggest that Pacap has an impending effect on the regulation of food intake.  
Corticotropin releasing hormone (Crh): 
The Crh is a peptide, which is secreted in the PVN of hypothalamus181, in placenta and in a 
number of peripheral tissues. Crh serves as an integrator of adaptive responses to stress, 
gastrointestinal function, inflammatory processes, cardiovascular processes, and influences 
food intake182. Crh and its related peptides regulate feeding behavior and stress responses in  
vertebrates, including fish, amphibians, birds and mammals183. Intracerebroventricular (ICV) 
administration of Crh in the goldfish exerts an anorexigenic action180 that can be inhibited by 
Crh receptor antagonists183. 
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Somatostatin (Sst): 
Somatostatin is a peptide hormone that is found in periventricular and paraventricular (PVN) 
nucleus, ventromedial, arcuate nucleus and in the brainstem of the nucleus of the solitary tract 
(NTS)184,185. Somatostatin binding with  Somatostatin receptors regulates the endocrine 
system and inhibits the secretion of several secondary hormones such as insulin and glucagon 
secretion (http://www.britannica.com/science/somatostatin). Injection of Somatostatin or 
Somatostatin agonist intracerebroventricularly (ICV) into the brain increased food intake in 
rats at low dose186–188. However, at higher doses injection of Somatostatin decreased food 
intake in mice and rats162,187,189,190. The decrease food intake at higher doses may be due to 
the occurrence of other competing behavioral changes and peripheral circulation leakage191 
where the peptide exhibits inhibitory effects192. Whereas, activation of Somatostatin signaling 
in brain by ICV injection of stable Somatostatin agonists at low doses strongly increases food 
intake in rodents and non-mammalian species193. 
Melanocortin-4 receptor (Mc4r) gene: 
The MC4R is encoded by 333-amino acid protein having single exon and found to be 
expressed primarily in the brain194. The Mc4r gene belongs to the large super family of G-
protein coupled receptors having the common structural feature of seven transmembrane 
spanning protein domains195. Mutations in the Mc4r gene account for obesity cases. A 
common variant of the Mc4r gene causing increased appetite and decreased satiety are 
distributed in the population and results the risk for increased weight gain. MC4R belongs to 
the large super family of G protein-coupled seven transmembrane receptors (GPCRs), whose 
subtypes are identified so far couples in a stimulatory manner to adenylate cyclase196. The 
Mc4r gene is widely distributed in the brain, predominantly in hypothalamus concerned in 
appetite as well as body weight regulation197,198. There are different melanocortin pathways 
that regulate food intake and energy expenditure199. The endogenous agonist α-melanocyte 
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stimulating hormone (αMSH), a peptide derived from Pomc and an antagonist Agrp106 
modulates Mc4r signaling. On the other hand, an adipocyte-derived hormone, leptin activates 
Pomc resulting in increased secretion of α-MSH and deactivates Agrp neurons in the arcuate 
nucleus of the hypothalamus200,201. The suppression of Mc4r signaling by Agrp or synthetic 
antagonists increase food intake and diminish the hypophagic response to leptin, as well as 
activation of Mc4r by αMSH or synthetic peptide agonists reduce food intake202,203. In mice, 
the regulation of firing activity of neurons from the PVN by α-MSH, and Agrp can be 
mediated independently of G-α-s signaling by ligand-induced coupling of Mc4r to the closure 
of inwardly rectifying potassium channel Kir7.1. Furthermore, Agrp is a biased agonist that 
by binding to Mc4r hyperpolarizes neurons and opening Kir7.1 and inhibits α-MSH binding. 
As a result, Kir7.1 signaling shows a melanocortin-mediated regulation of energy 
homeostasis within the PVN204. The paraventricular hypothalamus Mc4r-expressing neurons 
act as a functional target for orexigenic arcuate nucleus Agrp expressing neuron and explicit 
to lateral parabrachial nucleus satiety-promoting circuit, the activation of which encodes 
positive valence in calorically depleted mice205. 
Single minded1 (Sim1) gene: 
The Sim1 gene encodes the bHLH-PAS (basic helix-loop-helix–Per Arnt Sim) structural 
protein domain206 and form subgroups of bHLH super family of transcription factors. By the 
presence of bHLH and PAS domain Sim1 gene acts as a critical transcriptional factor and 
strongly expressed in the development of the PVN207. By using the PAS domain wild-type 
Sim1 gene bind with Arnt2 to form a hetero-dimer and exert a strong transcriptional activity 
for functioning in the development of the hypothalamus208. The human Sim1 and Sim2 genes 
exert a strong homology with mouse Sim1 and Sim2 in the amino-terminal part of the protein 
in which the conserved bHLH (basic helix-loop-helix), PAS (Per-Arnt-Sim) and PAC (PAS 
associated C-terminal) domains are located.  PAS domain serves as a potent protein-protein 
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interaction interface and regulation of the dimerization activity of the bHLH domain to 
induce the transcription of target genes209,210. 
Sim1 gene is  allied with human monogenic obesity and chromosomal aberrations in Sim1 
locus results in hyperphagic obesity in human211,212. Sim1 gene is necessary for the 
development of the paraventricular nucleus of the hypothalamus (PVH), medial amygdala, 
supraoptic nucleus (SON) and nucleus of the lateral olfactory tract (NLOT)199,207,213. The 
PVH is the critical regulator of appetite, energy expenditure and body weight. The PVN, 
supraoptic hypothalamic nuclei and anterior paraventricular nuclei are responsible for the 
production of multiple neuropeptides, including Oxytocin, Vasopressin, Trh and Somatostatin 
etc. These neuropeptides have been implicated in energy balance in experimental 
models214,215. The role of Sim1 gene is not limited to the formation of the PVN or its 
projections only.  In regulating body weight it also plays an important role in the leptin–
melanocortin–oxytocin pathway215 where, the Oxytocin may exert a tonic stimulatory effect 
on nucleus tractus solidarius (NTS) neurons to reduce the amount of meal216,217. Sim1 
haploinsufficiency affects the anterior periventricular nucleus expressing, Oxt, Avp, Trh, Crh 
and Sst by and mediate the hyperphagic obesity of Sim1 deficient mice. The Oxt  mRNA was 
drastically reduced in the hypothalamus of Sim1 deficient mice in compared with controls216. 
The neurotransmitter glutamate also exhibits a critical role to mediate the function of Mc4rs 
on sim1 neurons in regulating both energy expenditure and food intake218.  The deficiency of 
Sim1 gene exhibited increased hypothalamic Pomc level, but  showed and impaired action of 
melanocortin-mediated anorexia and decrease activation of paraventricular nucleus neurons. 
This result suggested that Sim1 functions downstream of the Mc4r in Sim1 heterozygous 
mouse219. In supporting  with this evidence it also stated that, overexpression of Sim1 
partially rescued the Ay, and diet induced obesity of the Ay mouse by the normalization of 
food intake, but has little or no effect on their energy expenditure219. Conditional deletion of 
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Sim1 with Cre93 and Cre159 generated a strong phenotype that exhibited a significant 
decrease of Oxytocin, Mc4r and Sim1 mRNAs expression with the development of early 
onset of obesity215. Tamoxifen induced neural inactivation of Sim1 gene in mice showed 
decreased expression of PVN neuropeptides, especially Oxytocin, Vasopressin, Crh and Trh 
but  no change in energy expenditure. It also revealed that the survival of PVN neurons does 
not depend on  Sim1 expression. The results confirm the previous evidence that Sim1 
regulates body weight by acting both  physiologically as well as developmentally220. 
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Chapter 2. 
Research plan and objectives 
 
In order to identify a gene essential for a defined biological phenomena, forward genetic  
strategy acts as one of the most influential approaches and enables us to understand the 
genetic basis of human biology and disease, when applied in model animals1 such as fruit fly 
and  mouse. Among the various sources of generating phenotypic variation the chemical 
mutagen N-ethyl-N-nitrosourea (ENU) performs as a powerful mutagen for spermatogonial 
cells of mouse and widely using in generating mutagenesis of mice8,221–223. There have been 
many research areas in which candidate gene approach would not work because the loss of 
function effects caused by gene targeting are often masked by the redundant and 
compensatory regulation of target phenotypes. The forward genetic strategy that is phenotype 
driven and hypothesis-free approach, will help to find out novel genes which may play a 
crucial role in the target behaviors of phenotypes. 
The major obstacle of the forward genetics is that it usually takes more than five years from 
the phenotype screening to identify a candidate gene mutation. However, the recent advance 
in DNA sequencing technology have been sped up the process from the linkage analysis to 
identified candidate mutations. A key to successful forward genetic study is the similarity in 
genome DNA between a mutagenized strain and counter strain. Since C57BL/6 (B6) 
substrains have the almost same genetic background40,224, B6J and B6N are ideal strains for 
forward genetic study. Hence, by the combination of using B6 substrains, routine use of in 
vitro fertilization and whole exome sequencing is a better way for new gene discovery.  
In order to examine the sleep/wakefulness abnormalities in randomly mutagenized mice, our 
laboratory has been undertaken a large-scale forward genetic screen of sleep abnormalities. 
Throughout the screening of more than 5,000 mutagenized 
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G1(C57BL/6JxB6J)/F1(B6JxB6N) males we have found several mice that exhibited with an 
obvious obesity phenotype. Although several genes such as leptin and Mc4r39,85,86 have been 
found to be mutated through the recessive screening for obesity, there has been no successful 
dominant obesity screening, which may be due to the significant QTL effects between the 
mutagenized and counter strains on body weight and the low fertility of obese mice. 
However, our screening scheme may overcome these obstacles by the use of B6 substrains 
and a routine use of in vitro fertilization. Thus, we started a forward genetic study for obesity. 
The purpose of the current study was two fold; i) to evaluate the efficiency and 
reproducibility of our new forward genetic scheme by conducting the dominant screening of 
obesity, 2) to identify the gene mutation that causes obesity in a dominant inheritance. If the 
identified gene is a novel player in the homeostasis of energy metabolism, the mutant mice 
may afford a new genetic model for the human metabolic syndrome, as well as new insights 
into the pathophysiology of obesity. 
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Chapter 3. 
Materials and methods 
 
3.1. Animals and mutagenesis strategy225 
The mice were kept singly in the cages at 23-25°C with free access to water and normal diet 
under a 12 h-12 h light-dark cycle. The experimental procedures were carried out under the 
guideline of RIKEN Bioscience Technology Center in ‘Outline for conducting animal 
experiments’ (Issued August 1999, revised October 2001) and also with the guidance of 
animal resource center of University of Tsukuba, Japan. The stock male mice were supplied 
from CLEA Japan, Inc. The ENU (Sigma-Aldrich) was injected intraperitoneally to the wild-
type male C57BL/6J mice at 8-10 weeks of age with 85-100 mg/kg body weight twice at 
weekly intervals. After a sterile period (10-11 weeks) the injected males were mated (IVF) 
with C57BL/6J or C57BL/6N wild-type female to produce G1/F1 progeny.  Phenotypic 
screens of G1/F1 progeny were routinely carried out. The phenodeviant F1 male mice were 
again mated with C57BL/6N wild-type females to produce N2 progeny (Fig. 3a). The N2 
progeny was then used for the inheritance testing of obesity and mapping36,38. 
3.2. Screening method for heritability of obesity225 
In order to examine the sleep/wakefulness abnormalities, we have screened more than 5000 
randomly ENU mutagenesis G1/F1 mice. In parallel with examining the sleep/wakefulness 
abnormalities we also have dominantly screened the same randomly mutagenized group of 
mice for obesity. At the age of 12 weeks, G1/F1 male mice were implanted an EEG/EMG 
electrode under isoflurane anesthesia and then examined for sleep/wakefulness abnormalities. 
In this study, total thirteen obese male G1/F1 mice were selected to generate N2 progeny via 
in vitro fertilization method. The body weight of the N2 mice was measured weekly from the 
age of 10 weeks to 26 weeks and  bi-weekly from the age of 28 weeks to 34 weeks. The N2 
progeny was examined for heritability of obesity and linkage analysis. If the body weight at 
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least 30% of N2 progeny exhibit similar obesity to their founder mouse, then the obesity 
phenotype was considered as heritable. Besides, the body weight of the N3 mice of Obese-10 
and Obese-13 was measured weekly from the age of 6 weeks to 11 weeks. 
3.3. Linkage analysis225 
In order to perform the linkage analysis, tissue was collected from the N2 mice by tail 
cutting. The genomic DNA was isolated and purified by using a DNeasy Blood & Tissue kit 
(Qiagen). Through the use of custom Taqman genotyping assay to determine the SNPs of 
each N2 mice. The assay was performed  by Applied Biosystems 7900HT followed by Fast 
Real-Time PCR System and controlled by TaqMan Genotyper (Thermo Fisher) as well as 
SDS2.2.2 software.Based on the polymorphism data between C57BL/6J and C57BL/6N mice 
the custom probes were designed41. The J/qtl software (Jackson Laboratory) was used to 
perform QTL analysis. For this linkage analysis total 93 markers (Table 1) have been used for 
whole chromosomes. Among them, 6 SNPs markers were used in the region of 
chromosome10, and 4 SNPs markers were used in the region of chromosome18.  In order to 
locate the association between phenotype and genotype the strain distribution patterns (SDPs) 
were constructed according to the descending order of body weight (from high body weight 
to lower body weight) of sample N2 mice using the body weight of 18 weeks and 26 weeks. 
Table-1: List of SNPs markers for linkage analysis: 
Chr Position Rs number 
B6J/B6N 
Forward primer (5'-3') Reverse Primer (5'-3') 
Chr1 3597640 rs32685032 
A/T 
CCCACACCCCATAATACTGACATAT AGTCTAATTTCATTCTCAGCCATTGGT 
Chr1 42424440 rs31362610 
T/C 
TGGCTTTCTCTTATATACTTTCCGATGTG GCAAACTCTGCCCATATGACTTAGT 
Chr1 61228463 rs13475886 
T/C 
TGGAGGAGTCAGGAAGAGAAAGG CTGGCCAAGACAGAATTAAGGAGAA 
Chr1 131282938 rs6327099 
T/C 
AGTAGGGTTTTGTATTGGCTTAGTTTGTT GAGGTAGATGGATTGTGGTTTAGCT 
Chr1 165062830 rs6341208 
A/T 
AACATGCTGACTCCTCGATTGTAAA TGATCGTTCTGATTGTTGAAATCCCTTT 
Chr1 196072469 rs242712390 
C/A 
CCAAATTTCAGGAGTGATGCATTCAG TCTATCTGCAAAGAACCTCTCATACCT 
Chr2 7991482 rs13476337 
A/T 
CAGGATCCAAGCTTACTGACTCAT GTGAAATTGATGACTCTCAAAATGAAGGT 
Chr2 44998528 rs33488914 
A/G 
GCAAGCGCATTGATGTTTTCATAGT ACTCAGCTGGGAGACTTCCT 
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Chr Position Rs number 
B6J/B6N 
Forward primer (5'-3') Reverse Primer (5'-3') 
Chr2 78639333 rs33162749 
C/T 
TCTACTCTCCAGTTCAACAGTGGTA GACACAGGCTTAACATGAGTATGGT 
Chr2 105914300 rs227312316 
G/A 
GCCTTAAAGTTTACAAAAAGCATGCCATA CAAAACAAAAGATTACATATAGAAATAT TGAGAACGAACT 
Chr2 138305756 rs13476801 
T/C GAATGTGACATTATGTTCATATTCATAATT 
AAATTTATTCCTTTT CCTCAATCTACAGTCAGGCCAAATT 
Chr2 178997069 rs29673978 
C/T 
GATCTTGGCAATGTATGAGGGATGA GCACTTAACAGTCTCAGCATTAGCT 
Chr3 5370727 rs13476956 
C/T 
CAGATTCATCTTCCTGCTAGACACA TCCTAGATTACATATTTTCATAATTGA TAACTTTCTGCAT 
Chr3 27139753 rs237712466 
T/G 
GTCACCGAGCATGTGTAAACC GCGGAAACTCACAAATCTTCATCTT 
Chr3 73922455 rs31154737 
A/T 
ATCCAAGCTCTGAATTGACCCATT CTGGCCCTTTCACACATCTCA 
Chr3 107273295 rs31321678 
A/G 
CCTGCAAATTGTGCTCTGGAAA GTGGTGGTCTTTGCCTCTGT 
Chr3 151882540 rs31594267 
A/C 
TCTTGCCTCCGACCATGAAATG TCAGCAGTTTTATCTTAGTCAGGTTTCAA 
Chr4 6301848 rs32143059 
G/A AGCTCATGTTGATATGAAAAATAAATT 
CTTAAAAAGGATT 
ACATTTTATTAAAAATCATTAGAGTTCTA 
TGTCTTGGGT 
Chr4 28249560 rs13477622 
T/C 
TGAAGGTCTCCATTGCCACATG CAGTGAATATTCCTAATATAAGTGAAGCTGGTT 
Chr4 65605269 rs13477746 
T/C 
CCTTCTCCAATCCATTTCTCACTGT AATCTGATAATATAGCTATTATAAAAAAT GTAGTGTGCCA 
Chr4 110323003 rs245725397 
C/T 
GAGCAGTCCATCTTGTATATTGGAACA AACGGAAAGCCAGTGTAACCTAAA 
Chr4 155284926 rs6397070 
T/C 
AGTGTCCCTTGTGTCCAATGAAA TCCAAAGCTCTCTTGCCTTGAG 
Chr5 4547791 rs247844351 
C/T 
GCCGAATGGCATAGCAGAATT CTGGATGGCGTCAGAGTTTCT 
Chr5 41153028 rs33508711 
C/T 
GAATCTGTGATCGCTACCTGTATCC AAGAGAAAAAGGAGCCTTTGTGAGA 
Chr5 71133300 rs13478320 
C/A 
GATACTGTTGTAGTCATTTCAGGAAACCA GATGTTTCTGGTTCTTTGAGAGATGC 
Chr5 92510104 rs33249065 
A/G 
ACCAAGGCACAAAAAAACCCAATTT TGGCAGATGTGTGTTTGATAGCT 
Chr5 117909356 rs3662161 
A/G 
ACCAAGGCATAGCATAGCATAGC GTAAAAGCACCTGTATTGGGTTTGG 
Chr5 150428596 rs33208334 
T/C 
AACATGGCCATAACCAACTGTACT GGCTCTGCAGTAAGCACTTGTTATA 
Chr6 6183941 rs30450019 
A/G 
AGGCAGCTGTTAAATGCTAGCT GCAAATCAGAAAGGTGGGAAAGAGA 
Chr6 44236335 rs30892442 
A/C 
TGTTCGACAATTCTGACTGAGCTC AGTGTGCTATACAACAAAGACAATCGT 
Chr6 67237174 rs6157367 
T/A 
CTACTCTTAAAGCAGTCCTGTCACT TCTCTTACTTTTTTGACTATGGATAAATGGCT 
Chr6 117420898 rs13478995 
C/G 
AGCAATCAGAGGAGGAAGAACCT GCACCTCACATTTCTCTTCTACCA 
Chr6 141021111 rs235068709 
G/T 
GCGGTCTCACCATATTGTCCTA CAGTTGTATGGCTGGAGATGCTT 
Chr7 6929448 rs242748489 
G/A 
CCATCTTCCTCATGAAGAATATTAAGCTACA CGGATCTCATGATGTGTCCCTTTTA 
Chr7 38216957 rs31221380 
A/C 
TCTGCCTCTCTTTTCTCCTATTCCT CCCGTTTGACTGAAAAGCACAATAT 
Chr7 78961795 rs32060039 
C/G 
GGAAGCGTGGGCTCCTC TGCAATGCTTTTCCTGGAGTAACTT 
Chr7 110121823 rs243575509 
C/T 
CTTTCAGCCCTTGAGGCAATG TGCTCATCCTCTTCTCCTATGCA 
Chr7 136179208 rs13479522 
A/G 
CTGTCCCATCTGTTGAGAAGCA GTAAGATGTGCACTCAGCATTGAC 
Chr8 10521755 rs13479605 
C/A 
GCATGTGCATGGGCTTTAATTAAGT CTGACAGTCACTGGCTTCCT 
Chr8 30207547 rs13479672 
T/C 
AATGATATGCACCACAGCACTCT GCACTATTGCTAAGGGAAACGGATT 
Chr8 77477256 rs32729089 
T/A 
CTACCCTATGTCAGGTGTTTTCATCA GGGTGAGGTATTTGTGGTCTGTTA 
Chr8 94031516 rs33601490 
T/C 
CTTGGTGCTATGGCTTTAAAAGGTT CCTCAGATGTCTTACTCATAACAAGCT 
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Chr Position Rs number 
B6J/B6N 
Forward primer (5'-3') Reverse Primer (5'-3') 
Chr8 126154896 rs32577205 
A/G 
GGAGGAGTCTCTAATTGCTTTTATGGT GGGACTTTGTGATCACATCTAGCTT 
Chr9 6238770 rs33672596 
A/A 
GTGCACACATGAACCTGACAAA GGCCCCCTAATTATCATTGATCATACA 
Chr9 30964211 rs13480122 
T/C 
ACAAAGCAGAGAGAGGCTGTAC AGATCCCAGACCTCGGTGAG 
Chr9 52593224 rs29644859 
T/G 
AGTGCTCTACAGTGCAAGAAATTGA GTCTCCTGACTCTTAAGAATGGCAAT 
Chr9 85132792 rs260373537 
T/C 
TCAAGGTTCCTTCTGCCCATAAAAT GAGGACTGAAATGGATTCTAACAGGAAA 
Chr9 119550616 rs30431245 
T/C 
CAGGCTTGAGAGCAGTGGTATTTAT GGCAGAAAGGAAGTTTAAGGAGAGA 
Chr10 5315765 rs50477269 
A/G 
CTCTAAGTTTCCAGAAGGCAAAAGC AGACACTCTGTGCACTTAGAGATTCT 
Chr10 33372829 rs13480575 
T/C 
GCAGTCTCTGAAGGTCATTTTACCA TCTCCTTGAAGGTTGCTGATCAC 
Chr10 57472268 rs13480619 
T/C 
TTTGACAACAGGCTTCCTACTCTTT TGGGCTTGTCCTAGTTTGAAAAGT 
Chr10 80258110 rs13459122 
T/A 
GGCAGCAACAATGTGTGAGATG CTCTGTCTTGTGATGACCTCTGT 
Chr10 108815683 rs13480759 
C/T 
GGTTTTCTTGGCTTTTGTCTTCTGT CGTGGAGGGATTAGAAGACACTT 
Chr10 126196231 rs236992510 
G/A 
CCTCATCAACCACTCCAAGGT CTCCTGAATTCTGCATCCAGTGA 
Chr11 4408733 rs3659787 
G/A 
GCATGGTTCTAGCGCACGAA CAACCCTGGTTGCACAAATGAG 
Chr11 28247415 rs259140591 
C/T ACATAAGTGGTTTTCCCAGAATTATTTTT 
TATTTTCTT AAGGTGCTTCAGTATAAATAGATTTTTTTTTAAAT 
Chr11 47930884 rs13481014 
T/C TCTTACATGTTTTTATAATCTCCAGTGCATA
ATGT GCGAGACAAGTATTTCCTGATACTTATGTAT 
Chr11 79065732 rs13481117 
G/T 
AATCTTCCTTCTACCCCACCCA GAGGTCATGAGGTCAAGATTGTTCT 
Chr11 120168102 rs49027247 
T/C 
GGGAAGCCCATTGTAGAAGTATCAG GGCTCCCAGGCAAGGT 
Chr12 7460524 rs29142759 
A/G 
GTACATAAGTGCTTTTCCTGGACACT CTTTGCAGGTAGAGTTCTAAGAACTATGAATT 
Chr12 35152831 rs29487143 
G/C 
TGGTTCTATGCTTCAGTGTATTGCA ATTCCATTTATTACATATGCAAAATGTTCATCGT 
Chr12 63868521 rs29133146 
A/C 
GCTGTGGCTTGCTCTAGGA CCCCTCACCGAAGATGCTT 
Chr12 86986287 rs13481569 
G/A 
TGGGTGCGCTGTTTCAGATT GCTGGAATATTGAATGGCTTGGTTT 
Chr12 108071865 rs13481634 
A/C 
GCTGGACATGTTGCTTCTCACA GAGCACCTGTCTCCAGCAT 
Chr13 3427897 rs30039194 
A/A 
TCGCAACCCCAGCTCTTG ACCAGTCTCTCAATCCAACATGTG 
Chr13 41538155 rs3722313 
T/C 
TGCCTGCTCTGCCTTCTC GGAGACAGGTGAAGAGTGAGGAA 
Chr13 77550367 rs29802434 
G/C 
TCAGCGATACCCCATGTTAAAATCA GAAGACAAATACTGAGAGGCAAAGAGT 
Chr13 101979187 rs3702296 
A/G 
CCCATGTTATGGACTCAAGGAGTAG TCTTTACGCCTGCTTCCTCAATAAG 
Chr14 10769899 rs31187642 
G/A 
GGAAAGCAGGAAGCCAAGACA TGTTAGAGCAGATGGGAGGTTACT 
Chr14 37292635 rs31133670 
A/G 
ATTTCTGAAGTATGACCCGTATTACAACTC CAATTCTACATTTTATAGAGTAAAAAG AGAGAAAAATCTGG 
Chr14 74815528 rs30264676 
T/A 
CTATGGCAAAAGGGAAGTGCAAAT TTGTCACAACTGTCTTCCTTTCTGT 
Chr14 100024215 rs31059846 
A/G 
TCACCGTGAGTGGGCATTC TGCTTAAGACCTTTACCATGCATCTT 
Chr14 124508019 rs31233932 
C/T 
GCGTCAATCTACTCATGGTAAGGATATT TCAGTCTTCTCAGTCCCTAATGCTA 
Chr15 9686848 rs257670740 
T/C AAAATAACCCTAGAATTAACTTCCTGTCTTC
AG CCTTGCTTCAAAGCATACTCTTCCA 
Chr15 30543322 rs261563123 
C/T 
GGTCTTGGGTGACTCTGTGAAAG GGGAGTTTTTAGATCATTGACCTGTAGT 
Chr15 71462981 rs31858887 
T/C 
TCATTTTATTTGGCATCTGCCATTAGC TCAGCGTGGGAGTGAAATGATG 
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Chr Position Rs number 
B6J/B6N 
Forward primer (5'-3') Reverse Primer (5'-3') 
Chr15 97085796 rs31921278 
A/G 
TGTGTTAGCACTACAGTTGTTCATCA GGAGTGGCTTTGAGATCATTTAGACA 
Chr16 4207926 rs219190959 
C/T 
GCTTTAACAGTATGCAACCATTGGT GGGCTGCACTGGTAACTCTTC 
Chr16 17412172 rs4165065 
T/C 
CTCCTACAAACACCCTGAATGCT AGAAGTATATCAGAGATGTTCATGAGATGGAA 
Chr16 52740057 rs4187179 
T/C 
GTCTCCACGTCTGATGTCAAAGAG GCTGAATGGTAGATTTACCAGCTGTA 
Chr16 87819874 rs4214728 
T/C 
TGAAGCAGAAAGCAGTAACTTACCA CTTTGTTTCCTTGACCACATTTTCCT 
Chr17 5332903 rs4137196 
T/C 
GAATCTGATGCTGGCTGAATTGG GTCCATGGCTGTTACTTCTAAGCA 
Chr17 39307300 rs33334258 
G/A CAGTGGAATACTATTCAGATATGGAAAGAA
AAGT CTTTTAAGCCTGGATTACTACACTTTGG 
Chr17 60459368 rs13483055 
T/C 
TGCTTGTGGCAGAAAGATCTAATCA TGAAACTTCTCTGGACCTCCTCTT 
Chr17 93798641 rs229426697 
C/T AAAATTTATGTAACAATAAAGAGGCTAATG 
TTTTGAATCT TCTAGAGCTTTTAGGTGTGTTGTCAAG 
Chr18 15408257 rs13483221 
C/T 
GCTGTCCAGTGCAAGAGTCA ACCAACCTGGATGAGTCACATTTAG 
Chr18 35366160 rs13483296 
A/T 
TGTACAGCTAATTTAGCTATTCTGCACAT TGGTTGGTGCCCAGTACTTAAAA 
Chr18 54774495 rs13483369 
A/C 
AGAAGCCCTGTCATGAAAATCACAT GGGTGCCCCAAAATATTGTATGAAA 
Chr18 84686237 rs29690544 
T/C 
ACCTTCAGGCAGTCCAGTACT TCTCAGAGTTTCTCATCTTTAGGTGTACT 
Chr19 9101495 rs31112038 
G/C 
CCGGTGGGACCTTCATTTCTAAAA CCTAAGATGCCGTCATATACAAAGTCA 
Chr19 16676708 rs30709918 
T/C 
GTTTACAAGTAACAGCAGGCAACAG GTAAAACCTCCTGCATATCACTCTGA 
Chr19 38079901 rs30953636 
G/T 
GTTTGCAAAGCCAGATTTTCTCCTA GGTTCAGCAGGGTCCTTTGT 
Chr19 50050644 rs3724876 
G/T 
TCAGGCTTAGTTTTTTTAATGTCAGGAGAT CCTCAACGGAGCTTTGTCCTT 
 
3.4. Whole-exome sequencing225  
In order to perform the whole exome sequencing, tissue also was collected from the N2 mice 
by tail cutting. The genomic DNA was isolated and purified by using a DNeasy Blood & 
Tissue kit (Qiagen). According to the SeqCap EZ Developer Library kit (MM9 exome, 
cat#110624, Roche NimbleGen) from 500 ng of genomic DNA, the exome sequencing 
libraries were prepared. Sequencing of multiplexed library with 151x2 paired-end mode in 
NextSeq 500 sequencer (Illumina) was performed by i-Laboratory LLP sequencing platform 
(Tsukuba, Japan). Reads in FASTQ files were imported to CLC Genomics Workbench 
(Qiagen), trimmed by 1-base at 3' end, and mapped to the mm10 mouse reference which 
represents the C57BL/6J strain genome. Exome sequencing statistics were calculated for 
capture target region definition provided by SeqCap kit. Variant call was performed using 
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Basic Variant Detection tool where the potential variants were filtered against control mice 
variants. Nonsynonymous base substitutions and small InDels were identified based on 
ENSEMBLE transcript annotation. All of variants identified on chromosome 10 and 
chromosome 18 for each pedigree were verified by visual inspection of sequence tag 
alignment. The numbers of the total reads and of variants called of four obese mice from the 
Obese-10 and Obese-13 pedigrees were summarized in Table 1225. 
3.5. Mutation analysis and genotyping of mutant mice 
3.5.1. Isolation and purification of DNA from mouse tissue and agarose gel 
To isolate the DNA the tissue was collected from the sample mouse's tail/ear. The genomic 
DNAs were isolated by using QIAGEN DNeasy blood and tissue kit (QIAGEN). The isolated 
DNA was amplified by PCR reaction using specific primers. The amplification of the DNA 
was confirmed by running the amplified DNA sample through agarose gel electrophoresis 
(1.5 % gel, Run time 30 minutes at 100 volts). The amplified PCR products were purified 
using fast gene Gel/PCR extraction kit (Nippon genetics Europe GmbH, Germany). 
3.5.2. Direct sequencing of DNA 
For direct sequencing, the PCR products amplified from genomic DNAs were purified using 
a Fast Gene Gel/PCR extraction kit (Nippon Genetics). The sequencing reaction was 
performed using PCR products (purified) 50-100ng, forward and reverse primer 0.5 μl, big 
dye 1.0 μl, big dye terminator (v3.1) 1.5 μl and de-ionized water up to 20 μl. The reaction 
was initiated with hot start at 96°C for 1 min and followed by 25 cycles of 96°C for 30 Sec, 
50°C for 15 Sec, 60°C for 4 min and finally holds at 4°C. The PCR sequenced product was 
then purified by using fast gene dye terminator removal kit (Nippon genetics Europe GmbH, 
Germany). Finally, the DNA sequencing was analyzed by using the ABI 3130 sequencers 
(Applied Biosystems, USA). 
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3.5.3. Detection of gene mutation by dCAPS assay225 
To detect the Mc4r gene mutation through Derived Cleaved Amplified Polymorphic 
Sequences (dCAPS)  assay,  the genomic DNA was amplified using Mc4r S1 (5'-
TCCACCCGGCTGACCACGATGGGA-3') and Mc4r AS2 (5'-
GGCATCCGTATCCGTACTGT-3') and then digested with DdeI, which recognizes only the 
mutant Mc4r sequence. Electrophoresis on 2% gel showed a 353 bp band for the wild-type 
and 219 bp and 134 bp bands for the Mc4r mutant. The single nucleotide variant of the Sim1 
gene was also detected via the derived cleaved amplified polymorphic sequence (dCAPS) 
method using primers designed by dCAPS Finder 2.0 
(http://helix.wustl.edu/dcaps/dcaps.html). Genomic DNA was amplified using Sim1 dCAPS 
S1 (5'-TCCACCCGGCTGACCACGATGGGA-3') and Sim1 dCAPS AS2 (5'-
AAGGCTCAGGAGGAGAGAGG-3') to produce a FokI recognition sequence, GGATG, 
specific to the wild-type Sim1 sequence. PCR products were digested with FokI and then 
separated via electrophoresis on 2.5% agarose gel. FokI digestion of the Sim1 heterozygous 
mutant genome resulted in 189 bp, 152 bp, and 37 bp bands, while FokI digestion of the wild-
type genome results in 152 bp and 37 bp bands.  
3.6. Clinical biochemical test225 
At the age of 12 weeks the blood samples (200 µl) were collected from the tail vein or orbital 
sinus of mice under anesthesia at the late light phase in a fed condition. The samples were 
then centrifuged to separate the serum from the blood and stored at -80ºC until use. 
According to the protocol of ultra sensitive mouse insulin/leptin (ELISA) kit (Morinaga 
institute of biological science, Inc. Yokohama, Japan) the serum insulin/leptin level was 
measured and the absorbance was measured by using ARVOTM X5 2030 multi label reader 
(PerkinElmer, USA). The glucose level of mice was measured by collecting blood from the 
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tail vein using glucometer “Glu-test every” kits (Sanwa Kagaku Kenkyusho Co. Ltd. Japan) 
at the age of 9 weeks, at late light phase in a fed condition. 
3.7. Luciferase assay 
3.7.1. Plasmid construction225 
Genomic cDNA of mice was synthesized from the hypothalamic tissues. Full-length mouse 
Sim1 and Arnt2 cDNAs were amplified from mouse hypothalamic cDNA, which was reverse-
transcribed from mRNA prepared using a Prime Script RT kit (Takara). By the use of In-
Fusion HD Cloning kit (Takara-Bio) these Sim1 cDNA and Arnt2 cDNA were then 
subcloned into pcDNA3.1 vector. Using KOD plus a mutagenesis kit (Toyobo) a single 
nucleotide substitution was introduced into Sim1 cDNA to express SIM1(M143K). The 
Luciferase reporter plasmid 6xCMEAd2MLP-pGL3 vector was constructed by inserting a 6x 
CNS midline enhancer (CME) sequence of the Drosophila toll4 gene226 and TATA box into 
the upstream region of the firefly luciferase gene of the pGL3-basic (Promega) according to 
pML/6C-WT vector227 using ligation reaction. The presence of the mutation in the sub-cloned 
vectors and also the WT sequence were checked and confirmed by direct sequencing using 
ABI 3130 Genetic Analyzer (Applied Biosystems, USA). All of the plasmid vectors were 
transformed into DH5-α, cultivated and finally purified to use.  
3.7.2. Reporter assay of SIM1 transcriptional activity225 
Luciferase assay was performed to observe the SIM1 transcriptional activity in cells 
transiently expressing WT or mutant SIM1.  HEK293 cells were maintained and cultured in 
DMEM supplemented with penicillin/streptomycin and 10% fetal bovine. The cultured cells 
were plated in 24-well plates at a density of 50,000 cells per well. After 24 hours, cells were 
subjected for transient transfection with pcDNA3.1-Sim1 (50, 150, 300 ng) or with 
pcDNA3.1-Sim1(M143K) (150, 300 ng), pcDNA3.1-Arnt2 (150 ng), pML-6xCME-Luc (150 
ng), and pRL-SV40 (40 ng) per well using Lipofectamine X (Life Technologies). By adding 
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pcDNA3.1 the total amount of transfected plasmids was adjusted to 640 ng in each well. 
Forty-eight hours post-transfection, the luciferase activity of the cells were assayed by using a 
Dual-Luciferase Reporter Assay System (Promega). Each assay was performed in triplicate 
and repeated three times. Firefly luciferase activity was normalized to the Renilla luciferase 
activity for each well228. 
3.8. Measurement of daily food intake and epididymal fat225 
At the age of 8 weeks the N3 male mice were housed individually and supplied chow diet 
food (MF; Oriental Yeast). The mice were allowed one week for habituation of taking food 
from the food jar. After the one week habituation of food intake the amount of daily food 
intake was measured at every 24 hours in normal condition for seven consecutive days. At the 
age of 12 weeks of N3 mice we had dissected the intra-abdominal white adipose tissue 
(WAT)/epididymal fat and measured the weight of epididymal fat by electric balance. 
3.9.  Production of diet-induced obesity mice225 
In order to the production of the diet induced obese mice, the C57BL/6 mice at 3 weeks of 
age were subjected to feed a high-fat diet (D12492; Research Diet). The high-fat diet 
provided 5.2 kcal/g (60% fat, 20% carbohydrate and 20% protein, ) whereas, the low-fat diet, 
or normal chow, (MF; Oriental Yeast) provided 3.6 kcal/g (13% fat, 61% carbohydrate and 
26% protein). These high fat diet feeding was continued up to the age of 9 weeks. After 9 
weeks of being fed the high-fat diet, mice were sacrificed at ZT11. 
3.10. Collection of tissue and preparation225  
In order to measure the mRNA expression level of hypothalamic genes/neuropeptides the 
hypothalamic tissue was collected from N3 male mice. The mice were supplied chow diet 
food. At the age of 12 weeks the mice were deeply anesthetized with sodium pentobarbital 
(50 mg/kg body weight) and then sacrificed via cervical dislocation. The brain of the mice 
was rapidly removed and the medial hypothalamus was dissected on ice based on the 
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following boundaries: rostral, the optic chiasm; caudal, the mammillary bodies; 1 mm 
bilateral from the midline; and 1.5 mm dorsal of the ventral surface. This dissected tissue 
included the arcuate nucleus, ventromedial hypothalamic nucleus, dorsomedial hypothalamic 
nucleus, paraventricular hypothalamic nucleus, anterior hypothalamic area, and the medial 
half of the lateral hypothalamic area. After collection of the brain, it was rapidly stored under 
liquid nitrogen and finally stored at -80oC up to use. This tissue was then used to isolate RNA 
using the RNeasy Lipid Tissue Mini kit (Qiagen, Chatsworth, CA). The isolated RNA also 
stored at -80oC. 
3.11. Quantitative RT-PCR analysis225  
The cDNA synthesis by the using the isolated RNA with oligo dT primers and a Prime Script 
reverse transcriptase kit (TaKaRa). Then the real-time quantitative PCR reactions were 
performed with ViiA7 Real-Time PCR System (ThermoFisher) using SYBR GREEN PreMix 
Ex Taq (TaKaRa). In order to the quantitative RT-PCR analysis of the hypothalamic genes, 
the following PCR primers were used: Agrp forward, 5'-TCCCAGAGTTCCCAGGTCTA-3'; 
Agrp reverse, 5'-GCCAAAGCTTCTGCCTTCT-3'; Avp forward, 5'-AGGATGCTCAACA 
CTACGCTCT -3'; Avp reverse, 5'-ACTGTCTCAGCTCCATGTCAGA -3'; Crh forward, 5'-
GAAAGGGAAAAGGCAAAAGAA-3'; Crh reverse, 5'-GTTAGGGGCGCTCTCTTCTC-3'; 
Gapdh forward, 5'-AGAACATCATCCCTGCATCC-3'; Gapdh reverse, 5'-CACATTGGGG 
GTAGGAACAC-3'; Ghrh forward, 5'-CTCTTTGTGATCCTCATCCTCAC-3'; Ghrh 
reverse, 5'-AGTTTCCTGTAGTTGGTGGTGAA-3'; Mc4r forward, 5'-GCCAGGGTACCAA 
CATGAAG-3'; Mc4r reverse, 5'-ATGAAGCACACGCAGTATGG-3'; Mch forward, 5'-TGC 
TGAGTCCACACAGGAAA-3'; Mch reverse, 5'-GCCAACATGGTCGGTAGACT-3'; Npy 
forward, 5'-TACTCCGCTCTGCGACACTA-3'; Npy reverse, 5'-TCACCACATGGAAGGG 
TCTT-3'; Orexin forward, 5'-GGGTATTTGGACCACTGCAC-3'; Orexin reverse, 5'-CCCA 
GGGAACCTTTGTAGAAG-3'; Oxytocin forward, 5'-GCCAGGAGGAGAACTACCTG-3'; 
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Oxytocin reverse, 5'-CTCCGAGAAGGCAGACTCAG-3'; Pacap forward, 5'-CTATGGCTA 
TTGCTATGCACTCTG-3'; Pacap reverse, 5'-CAACCTGGGGAAGACTCATTTAG-3'; 
Pomc forward, 5'-AACCTGCTGGCTTGCATC-3'; Pomc reverse, 5'-TTTTCAGTCAGGGG 
CTGTTC-3'; Sim1 forward, 5'-CCTCCATCCACAGAATCCAC-3'; Sim1 reverse, 5'-TGATA 
CTGTTCGGTGCGGTA-3'; Somatostatin forward, 5'-CTCTGCATCGTCCTGGCTTT-3'; 
Somatostatin reverse, 5'-AAGTACTTGGCCAGTTCCTGTTT-3'; Trh forward, 5'-GAAGG 
TGCTGTGACTCCTGAC-3'; Trh reverse, 5'-ATCTAAGGCAGCACCAAGGTC-3'. The 
averages of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA were used for 
normalization. A relative quantification method was employed for the quantification of target 
molecules by calculating the ratio between the amount of the target molecule and a reference 
molecule within the same sample, according to the manufacturer’s protocol. The reactions 
were performed in duplicate and the results were averaged. 
3.12. Statistical analysis225  
The significance of differences between two groups was assessed by two tailed t test. Data of 
SIM1 luciferase assay were analyzed by one-way ANOVA followed by Tukey's post-hoc 
test. The body weight data were analyzed by one-way repeated ANOVA followed by Tukey's 
post-hoc test. The qPCR data were analyzed by two-tailed t-test with Bonferroni correction 
for multiple comparisons. Sample sizes were determined using R software based on the 
averages and standard deviations that were obtained from small scale experiments. The 
experimenters were blinded to genotypes and treatment assignments. Statistical analyses were 
performed using SPSS Statistics 22 (IBM) and R software. All data were tested for Gaussian 
distribution and variance. Homogeneity of variance was tested for using Levene’s test225. The 
differences were considered as statistically significant if P < 0.05. Data were expressed as the 
means ± SEM. 
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Chapter 4. 
Results                                                                           
 
4.1. Screening strategy to establish obese pedigree225 
In order to screen of randomly mutagenized mice for sleep/wake disorder, ENU was injected 
into C57BL/6J (B6J) wild-type male mice (Go mice) and crossed with C57BL/6J (B6J) or  
C57BL/6N (B6N) wild-type female mice to produce G1/F1 mice. In parallel with 
sleep/wakefulness screening of these randomly mutagenized B6J/B6N G1/F1 male mice, we  
performed dominant screening for obesity by using the same mice (Fig. 3a). In this project, 
we have dominantly screened more than 5000 phenodeviant G1/F1 males. In this dominant 
screening of obesity, we have screened about 2500 mutagenized G1 mice. These G1 mice 
were produced by the in vitro fertilization (IVF) method, using the sperm of ENU-treated B6J 
male mice and egg of wild-type B6J female mice. In addition to the G1 mice, we also have 
screened about 2940 phenodeviant F1 mice. These F1 mice were produced by the in vitro 
fertilization (IVF) method, using the sperm of ENU-treated B6J male mice and egg of wild-
type B6N female mice. At the age of 18 weeks, the body weight distribution of these 
mutagenized F1 mice (n=2940) seems skewed toward overweight (mean = 33.3 g, standard 
deviation = 3.76 g and skewness = 0.85, Fig. 3b).  
Among the 5000 mutagenized G1/F1 mice, we have selected thirteen obese mice at several 
ages to include early-onset and late-onset obesity and performed dominant screening to 
establish the heritable obese pedigree. In this regard, we have chosen the five heaviest male 
mice by 18 weeks old, having body weight: 51 g, 48 g, 48 g, 46 g, and 46 g  and the other 
five heaviest male mice by 28 weeks old, having body weight: 53 g, 51 g, 51 g, 51 g, and 50 
g. We also have selected two obese mice by 32 weeks old, with high blood glucose levels 
having body weight and blood glucose: 52 g and 286 mg/dl, 53 g and 266 mg/dl. Besides, we 
have selected one mouse, which exhibited severe early-onset obesity, at the age of 10 weeks 
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having a body weight 47g. These thirteen obese male mice were then crossed with B6N wild-
type female mice through in vitro fertilization to produce N2 progeny (Fig. 3a). 
During the screening, the obesity phenotype was considered as heritable, if at least 30% of 
the progeny developed obesity same as in the obesity of founder mouse. As we searched the 
gene mutations which reproducibly cause dominant inheritance of obesity, thus the body of 
progeny below 30% was not allowed. Among the 13 pedigrees, two pedigrees, Obese-10 and 
Obese-13, showed heritable obesity. The offspring of the other 11 pedigrees did not show 
obesity and high blood glucose. The F1 founder mouse of Obese-13 pedigree having body 
weight 47 g at the age of 10 weeks, which was the most severe occurrence of early-onset 
obesity among all mice screened. Correspondingly, the F1 founder mouse of Obese-10 
pedigree, having body weight 51 g at 18 weeks old was the heaviest mouse at this age among 
all the mice screened, except for the F1 founder mouse of Obese-13. Consequently, the two 
founders of the heritable obese pedigrees were two most obese mice out of the 5000 mice 
screened. The inherited obesity characteristics of N2 mice were confirmed by measuring 
body weight (Fig. 6a,b and 10a,b). Linkage analysis of each pedigree exhibited a strong and 
single peak of LOD score. Subsequently, the direct sequence of candidate genes within the 
mapped regions led us to identify a single point mutation in Mc4r gene of the Obese-10 
pedigree and in Sim1 gene of the Obese-13 pedigree. Thus, among a total of 13 pedigrees, the 
Obese-10 and Obese-13 pedigrees, which were derived from a screening of the F1 mice, 
showed severe obesity at the N2 generation. 
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Figure 3. Obesity screening of randomly mutagenized mice225.  
(a) Ethylnitrosourea (ENU) was injected intraperitoneally to the C57BL/6J (B6J) males, 
which were crossed with C57BL/6J (B6J)/C57BL/6N (B6N) females to obtain the offspring 
(G1/F1 mice). The F1 mice were screened for obesity. By the use of sperm cells from an 
obese mouse the in vitro fertilization was performed with wild-type B6N eggs to obtain N2 
mice, which was examined for heritable obesity. If the pedigree showed heritable obesity, N2 
mice were further used for a linkage analysis. (b) The body weight histogram of all F1 mice 
screened at 18 weeks old. n = 2940. 
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4.2. Sec63 mutation of the Obese-13 pedigree225 
We performed whole-exome sequencing using two severely obese N2 mice (Body weight 
62.5 g and 60.6 g at the age of 26 weeks old) of the Obese-13 pedigree as well as two 
severely obese N2 mice of the Obese-10 pedigree (Table 1). The two Obese-13 obese mice 
showed heterozygous non-synonymous mutations in the Sec63 genes (Chr10: 42816394) 
along with Sim1 (Chr10: 50908536) gene, whereas, the two obese mice of Obese-10 pedigree 
did not. The mutant Sec63 gene was located within the mapped region of chromosome 10 
along with Sim1 gene (Fig. 7c) and no additional non-synonymous mutations were found 
there. To further segregate the Sec63 gene mutations for the obese phenotype, we performed 
direct sequencing of the Sec63 genes of five obese mice, which had a chromosomal 
recombination between rs13480575 and rs13480619 (the fifth column in Fig. 7d) and of 
randomly selected five non-obese mice. All obese mice exhibited mutations in Sec63 genes as 
well as in Sim1 gene, but the non-obese mice did not have any mutations either in Sim1 gene 
or in Sec63 gene. As a result, it was confirmed that, the mutations in the Sim1 and Sec63 
genes were co-segregated due to its proximity. In one obese mouse that is devoid of the 
B6J/N haplotype (the second column from the last in Fig. 7d) did not show any mutations in 
the Sim1 and Sec63 genes. This result demonstrates that obesity in this mouse may be caused 
due to the effects of other gene mutations or by any other unknown factors. In the Obese-13 
pedigree, the mutation in the Sec63 gene causes an isoleucine to methionine substitution at 
the residue 620. Sec63 gene is highly conserved from yeast to man229. It acts as an important 
part of a protein complex that translocates a newly synthesized peptide into the endoplasmic 
reticulum and also allied with autosomal polycystic liver disease230. But, none of the obese 
mice of the Obese-13 pedigree exhibited any cyst formation in the livers suggesting that the 
Sec63 gene does not affect in causing obesity, but we can not avoid the possibility. 
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4.3. Mc4r mutation of the Obese-10 pedigree 
4.3.1. Identification of single point mutation on Mc4r gene in the Obese-10 pedigree225 
The body weight of the founder F1 male mouse of the Obese-10 pedigree was 51 g at the age 
of 18 weeks. This phenodeviant F1 mouse was crossed with wild-type B6N female mice to 
produce N2 mice. Relative to the body weight distribution of the F1 mice, the body weight 
histogram of the Obese-10 N2 mice were clearly deviated toward overweight (Fig. 4a, Mann-
Whitney U test, p < 0.0001). The N2 mice of this Obese10 pedigree were used for the linkage 
analysis. The initial linkage analysis was performed by using 23 N2 male mice and identified 
a high QTL (quantitative trait locus) peak on chromosome 18 with an LOD score 3.94  
according to the body weight of 18 weeks (Fig. 4b). These N2 mice also showed a LOD score 
2.44 (Fig. 4c) which was measured according to the body weight of 26 weeks. These 23 N2 
mice also showed a high LOD score 3.94 on chromosome 2 which was measured according 
the body weight of 18 weeks (Fig. 4b), but it was gone near the base level when measured 
according to the body weight of 26 weeks (Fig. 4c). The reason of change of LOD score is 
due the change of body weight values of some mice (which have very close body weight 
values exhibited a variation comparing with one another) that was measured at 18th week and 
26th week.  Further analysis was focused only on the chromosome 18 using a larger number 
(n=206) of N2 mice (females, n = 99; males, n = 107), which exhibited a high LOD score 
(10.7 for males, 13.3 for females; 16.4 for total,) between rs13483369 (Chr18: 54774495) and 
rs29690544 (Chr18: 84686237) (Fig. 4e, f). Within this region, about 147 protein-coding 
genes are located, among them, the Mc4r gene exhibited a well known role in relation to the 
pathogenesis of human obesity231–234 and rodents235,236. Throughout the MGI (Mouse genome 
informatics) data base analysis, we found that except Mc4r gene, the other genes are not 
associated with causing obesity but we can not deny the possibility. Through the whole-
exome sequencing, we also found some genes mutations in different chromosomes (except 
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chromosome 18) of Obese-10 pedigree. We did not find any established report of these genes 
for association with causing obesity. According to the linkage analysis, the QTL peaks in this 
region is not so high (under the suggestive value), which assumed that the gene mutations 
within this region does not create a strong association to cause obesity.  
In addition, through the whole-exome sequencing we also did not find any common gene at 
chromosome 2, between the two sequenced mice sample. One of the mice showed mutation 
in Xirp2 gene and Lrp2 gene (Fig. 4d). But these genes are not associated with obesity. 
Actually, this QTL peak was associated with low body weight and the peak was near to the 
base level when measured according to the body weight of 26 weeks (Fig. 4c). Subsequently, 
through the direct sequencing of the entire Mc4r gene we have identified a single nucleotide 
substitution from thymine to adenine only in the obese mice of the Obese-10 pedigree (Fig. 
5a). This mutation caused a translation of amino acid from tyrosine to stop codon (Tyr-41-
Stop) on the codon 41 of the peptide. This amino acid (tyrosine) is located at the beginning of 
the first transmembrane domain of the MC4R protein (Y41X) (Fig. 5b). According to the 
result of whole-exome sequencing of two obese mice (Body weight 56.3 g and 54.5 g at the 
age of 26 weeks old) of the Obese-10 pedigree, the substitution of nucleotide thymine to 
adenine in the Mc4r gene (Chr18: 66859918) is located within the chromosome 18 region 
linked to the obese phenotype (Table 2, Fig. 4e). On the other hand, the two obese mice of the 
Obese-13 pedigree did not show any mutation in Mc4r gene (Table 2). Thus, the mutation 
(Y41X) of the Mc4r gene is considered to be responsible gene for causing obesity in the 
Obese-10 pedigree. In addition, the two mice (the last column in Fig. 4f), of Obese-10 
pedigree showed obesity without having the B6J/N haplotype. By direct sequencing, we also 
confirmed that these mice are devoid of any mutation in the Mc4r gene. This result, 
demonstrates that the effects of any other mutations or by other unknown factors may cause 
the obesity in these mice.  
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Figure 4. Mapping and analysis of sample mice of Obese-10 pedigree225. (a) The body 
weight histogram of  F1 mice and N2 littermates (bars) of Obese-10 pedigree. Here, the body 
weights of N2 littermates are deviated toward overweight compared with the body weight 
distribution of the screened F1 mice. (b) QTL analysis of the Obese-10 pedigree according to 
the body weight of 18 weeks (n=23) showed a high LOD score peak associated with high 
body weight on chromosome 18 associated with low body weight on chromosome 2. (c)  
QTL analysis of the Obese-10 pedigree according to the body weight of 26 weeks (n=23) 
showed a high LOD score peak associated with high body weight on chromosome 18. (d) The 
results of QTL analysis of the Obese-10 pedigree (n = 23) according to the body weight of 18 
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weeks exhibited a single peak of LOD score between rs33488914 and rs33622749 on 
chromosome 2. (e) The results of QTL analysis of the Obese-10 pedigree (n = 206) for body 
weight exhibited a single peak of LOD score between rs13483369 and rs29690544 on 
chromosome 18. (f) The results of haplotype analysis of Obese-10 N2 mice indicate that the 
mutation falls between rs13483369 and rs29690544 (arrow) on chromosome 18. 
 
Figure 5. Identification of a single nucleotide substitution of the Mc4r gene in Obese-10 
pedigree225 (a) Through the direct sequencing of the Mc4r gene identified a substitution of 
thymine-to-adenine specific to obese mice of the Obese-10 pedigree. (b) The mutation in the 
Mc4r gene results in a premature stop codon, which is located at the beginning of the first 
transmembrane domain of the MC4R, a G-protein coupled receptor. 
4.3.2. Mc4rY41X/+ mice exhibited higher Mc4r mRNA225 
To investigate Mc4r mRNA level through qPCR analysis, the cDNA was synthesized from 
hypothalamic tissue of mice at 12 weeks of age. The Mc4r mRNA content of Mc4rY41X/+ mice 
was significantly higher than that of Mc4r+/+ mice (Fig. 6d). 
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4.3.3. Mc4rY41X/+ mice generated severe obesity225 
The mice were kept in the single cage, fed a normal diet and the body weight was measured 
weekly. The N2 mice were weighed from the age of 10 weeks to the age of 26 weeks and the 
N3 mice were weighed from 6 to 11 weeks. The body weight of both N2 male and female 
Mc4rY41X/+ mice were significantly (p<0.001) greater than those of Mc4r+/+ mice (Fig. 6a,b). 
Besides, the body weight analysis of N3 mice of Obese-10 pedigree  exhibited a significant 
increase of body weight of Mc4rY41X/+ mice as early as 6 weeks of age (Fig. 6c). To measure 
the weight of epididymal fat we had dissected the intra-abdominal white adipose tissue 
(WAT) at 12 weeks of age. An excessive accumulation of white adipose tissue was found in 
Mc4rY41X/+ mice. The epididymal fat mass of Mc4rY41X/+ mice was significantly larger than 
that of Mc4r+/+ mice at the age of 12 weeks (Fig. 6e). To investigate serum leptin level blood 
serum was collected at 12 weeks of age. Consistent with a larger fat mass, Mc4rY41X/+ mice 
had a higher serum leptin level compared with Mc4r+/+ mice (Fig. 6f).  
4.3.4. Mc4rY41X/+ mice were hyperphagic225 
In order to measure the amount of food intake at the age of 8 weeks of N3 mice, we allowed 
the mice to take powdered food form a small food jar. After one week of habituation of 
feeding, at the age of 9 weeks the daily food intake was measured in every 24 hours for seven 
consecutive days. The Mc4rY41X/+ mice had a significantly (p<0.001) increased daily food 
intake compared with the Mc4r+/+ mice (Fig. 6g).  
4.3.5. Mc4rY41X/+ mice were pre-diabetic225 
At the age of 9 weeks of N3 mice, the blood glucose level was measured by collecting blood 
from the tail vein. Though the blood glucose level seems to be higher in Mc4rY41X/+ mice than 
the Mc4r+/+ mice, but statistically did not reach at significance (Fig. 6h). To investigate 
serum insulin level blood serum was collected at the age 12 weeks of N3 mice. As for 
glucose metabolism, where both Mc4rY41X/+ mice and Mc4r+/+ mice had almost similar blood 
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glucose levels, but the serum insulin level of Mc4rY41X/+ mice was significantly higher than 
that of Mc4r+/+ mice (Fig. 6i). The similar blood glucose level in obese pedigrees may be the 
result of compensation by the high insulin level.  
 
Figure 6. Metabolic phenotypes of Mc4r mutant mice225. (a) At the age of 26 weeks, the 
N2 generation of Mc4rY41X/+  male  mice (n = 11) showed higher body weight than Mc4r+/+ 
male mice (n = 11).  (b) At the age of 26 weeks, the N2 generation of Mc4rY41X/+  female  
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mice (n = 4)  also showed higher body weights than Mc4r+/+  female mice (n = 8). (c) The 
increased body weight of N3 mice indicates early-onset obesity in Mc4rY41X/+ mice (n = 16) 
relative to Mc4r+/+ (n = 16) mice. *** p < 0.001, one-way repeated ANOVA followed by 
Tukey's post-hoc test. (d) Increased level of Mc4r mRNA of Mc4rY41X/+ mice (n = 8) was 
observed than the Mc4r+/+ mice (n = 6). ) (e) The Mc4rY41X/+ mice (n = 6) exhibited increased 
epididymal fat weights than the Mc4r+/+ mice (n = 6). (f) Increased serum leptin level was 
found in Mc4rY41X/+ mice (n = 8) in comparison to the Mc4r+/+ mice (n = 8). (g) The amount 
of daily food intake of Mc4rY41X/+ mice (n = 6) was higher than that of Mc4r+/+ mice (n = 6).  
(h) Both  the Mc4r+/+ mice (n = 16) and Mc4rY41X/+ mice (n = 16) exhibited almost similar 
blood glucose level. (i) The  Mc4rY41X/+ mice (n = 8) exhibited higher serum insulin levels 
than Mc4r+/+ mice (n = 8). * p < 0.05, ** p < 0.01, *** p < 0.001, two-tailed t-test. Data are 
shown as the mean + s.e.m. 
4.4. Sim1 mutation of the Obese-13 pedigree 
4.4.1. Identification of single point mutation on Sim1 gene in the Obese-13 pedigree225 
The founder F1 mouse of the Obese-13 pedigree weighted 47 g at the age of 10 weeks and 
within the increase of age the body also increased and exhibited severe obesity showing body 
weight 55.5 g at 18th week and 63.5 at the age of 26th week. Subsequently, relative to the 
body weight distribution of the F1 mice, the body weight histogram of the N2 mice of this 
obese pedigree showed a deviation toward the overweight (Fig. 7a, Mann-Whitney U test, p < 
0.0001). These N2 mice were subjected for the linkage analysis. Initially, we performed 
linkage disequilibrium analysis of 49 N2 mice (25 males, 24 females)  of this Obese-13 
pedigree and found a single and strong quantitative trait locus on chromosome 10 with a high 
LOD score 7.19 measured according to the body weight of 26 weeks (Fig. 7b). Further 
linkage disequilibrium analysis focusing only on chromosome 10, using 172 N2 mice of this 
pedigree (male, n = 106; female, n = 66), exhibited a very high LOD score (25.6 for total, 
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22.8 for males, 10.0 for females) between rs13480575 (Chr10: 33372829) and rs13480619 
(Chr10: 57472268) (Fig. 7c, d). Within this region, About 96 protein-coding genes are 
located, but, only the Sim1 gene exhibited a well known role in the pathogenesis of obesity in 
humans237–239 and rodents207,215,219,240,241. Throughout the MGI (Mouse genome informatics) 
data base analysis, we found that, except Sim1 gene, the other genes are not associated with 
causing obesity, but we can not deny their possibility. Through the whole-exome sequencing, 
we found some genes mutations in different chromosomes (except chromosome 10) of 
Obese-13 pedigree. We did not find any established report of these genes for association with 
causing obesity. According to the linkage analysis the QTL peaks in this region is not so high 
(under the suggestive value), which assumed that the gene mutations within this region does 
not create a strong association to cause obesity. In chromosome18 of Obese-13 pedigree have 
suggestive LOD score about 3 (Fig. 7b) that is associated with low body weight, but we did 
not find any gene mutation through whole exome sequencing. The reason is that, Whole 
exome sequencing strategy can sequenced only the protein coding regions (exons).  The 
mutation may be located in the region of introns. Thus, we did not find the mutation by whole 
exome sequencing. To identify the gene mutation in this region, it is necessary to perform 
whole genome sequencing. Subsequently, through the direct sequencing of all 11 exons of the 
Sim1 gene we have identified a single nucleotide substitution in exon 4 specific to obese mice 
of the Obese-13 pedigree, which results the transversion of amino acid from methionine to 
lysine (Fig. 8a,b). 
According to the result of  whole-exome sequencing of two severely obese N2 mice (Body 
weight 62.5 g and 60.6 g at the age of 26 weeks old) of the Obese-13 pedigree, both of the 
obese N2 mice showed heterozygous non-synonymous mutations in the Sim1gene (Chr10: 
50908536) as well as in Sec63 gene (Chr10: 42816394). We also performed whole-exome 
sequencing of two severely obese N2 mice of the Obese-10 pedigree, but they did not show 
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any mutation in Sim1 or Sec63 gene (Table 2). Both mutated genes Sim1 and Sec63 found in 
the Obese-13 pedigree, were located within the mapped chromosomal region (Fig. 7c) of 
chromosome 10 and no other non-synonymous mutations were found in that region. In order 
to the additional confirmation, about the segregation of these two mutations in the obese 
phenotype, we performed direct sequencing analysis of the Sim1 and Sec63 genes in five 
obese mice having chromosomal recombination between rs13480575 and rs13480619 (the 
fifth column in Fig. 7d) and found that all of the obese mice showed mutations in both Sim1 
and Sec63 genes. We also performed direct sequencing of randomly selected five non-obese 
mice, but the non-obese mice did not show any mutation in Sim1 or Sec63 gene. This result 
suggested that due to the reason of proximity the mutations in the Sec63 and Sim1 genes were 
co-segregated. In addition, one mouse (the second column from the last in Fig. 7d), of Obese-
13 pedigree showed obesity without having the B6J/N haplotype. By direct sequencing, we 
also confirmed that the mouse is devoid of any mutation in the Sim1 and Sec63 genes. This 
result, demonstrates that the effects of any other mutations or by other unknown factors may 
cause the obesity in this mouse.  
SIM1 is a transcriptional factor which belongs to the basic helix–loop–helix-PER-ARNT-
SIM (bHLH-PAS) transcription factor family209. The mutation in Sim1 gene resulted in an 
amino acid substitution from methionine to lysine (M136K), which is located on the PAS A 
domain of the SIM1 protein (Fig. 8c). The substituted methionine is located in the Fα helix 
(Fig. 8d) of PAS A domain that is composed of five helices and five strands210. The α-helix 
sequence of PAS A domains exerts almost common structural modules of amino acids in all 
kingdoms of life. This high conservation of α-helix sequence of PAS A domains suggests a 
strong evolutionary conservation in functional features and involved in signal transduction in 
a wide range of individuals. 
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Figure 7. Mapping and analysis of sample mice of Obese-13 pedigree225.  (a) The body 
weight histogram of F1 mice and  N2 littermates (bars) of Obese-13 pedigree. Here the body 
weights of N2 littermates are deviated toward overweight compared with the body weight 
distribution of the screened F1 mice. (b) The results of QTL analysis of the Obese-13 
pedigree (n = 49) for body weight exhibited a single peak of LOD score on chromosome 10. 
(c) Additional QTL analysis focusing only on chromosome 10 using 172 N2 mice indicates a 
single peak (LOD score, 25.6) located between rs13480575 and rs13480619. (d) The 
haplotype analysis of Obese-13 N2 mice shows that the mutation falls between rs13480575 
and rs13480619 (arrow) on chromosome 10.  
BW 26 weeks
BW 26 weeks
Chr. 10
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Figure 8. Identification of a single nucleotide substitution of the Sim1 gene in Obese-13 
pedigree225 (a) Through the direct sequencing of the Sim1 gene identified a substitution of 
thymine-to-adenine specific to obese mice of the Obese-13 pedigree. (b) The substitution of 
nucleotide thymine (T)-to-adenine (A) is located in exon 4 of the Sim1 gene. Here, the coding 
regions are indicated by black box, while the non-coding regions are indicated by white box. 
(c) The 136th methionine residue located in the PAS A domain that is substituted to lysine. (d) 
The 136th methionine is well-conserved among vertebrates and invertebrates. The Fα region 
of the PAS A domain is indicated.  
4.4.2. SIM1(M136K) exhibited a significant decrease in transcriptional activity225 
The effect of the mutations on SIM1 transcriptional activity was evaluated by In vitro 
luciferase reporter assay. As SIM1 and other bHLH-PAS members form a heterodimer with 
ARNT2 via the PAS domain to induce transcription of target genes209,210, we measured the 
effect of transcriptional activity of SIM1 wild-type protein,  SIM1(M136K) protein and 
a b
c
d
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SIM1:ARNT2 dimer through luciferase assay. In consistent with the previous reports227, in 
this assay, we observed that the wild-type SIM1 protein singly exhibited a very low 
transcriptional activity, but, a strong transcriptional activity  was seen when  the SIM1 protein 
is co-transfected with ARNT2 (Fig. 9a). On the other hand, the co-transfection of 
SIM1(M136K) with ARNT2 did not show any transcriptional activity. We further performed 
the Luciferase assay to observe whether SIM1(M136K) interferes with the activity of wild-
type SIM1 by transfecting SIM1, ARNT2 and SIM1(M136K) together. The presence of 
SIM1(M136K) did not alter the transcriptional activity of the SIM1:ARNT2 dimer (Fig. 9a), 
resulting that SIM1(M136K) did not show any dominant negative effect on the wild-type 
SIM1 protein. Further, we assayed the transcriptional activity by increasing the SIM1 
content, where the ARNT2 content remaining stable, the result reveals that the luciferase 
units increased in a dose-dependent manner (Fig. 9b). However, we did not find any change 
in luciferase units at the increased amount of SIM1(M136K) with ARNT2. Thus, the 
mutation in the Sim1 gene produces SIM1(M136K) protein, which totally lacks its 
transcriptional activity. 
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Figure 9. Luciferase assay of SIM1 protein225. (a, b)The HEK293 cells were used for 
transient transfection with ARN2 expression plasmids, SIM1 wild-type and/or SIM1(M136K) 
expression plasmids, luciferase reporter plasmids and Renilla luciferase plasmids for the 
compensation of transfection efficiency. Bars indicate firefly/Renilla luciferase activity 
values relative to the mean firefly/Renilla values of the wild-type SIM1 (a, 150 ng; b, 50 ng)- 
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and ARNT2-transfected cells. *** p < 0.001, ### p < 0.001 vs. any of the SIM1 groups, one-
way ANOVA followed by Tukey's post-hoc test. Data are shown as the mean + s.e.m. 
4.4.3. Sim1M136K/+ mice exhibited lower Sim1 mRNA225 
To investigate Sim1 mRNA level through qPCR analysis, the cDNA was synthesized from 
hypothalamic tissue of mice at 12 weeks of age. The Sim1 mRNA content of Sim1M136K/+ 
mice was significantly lower than that of Sim1+/+ mice (Fig. 10d). 
4.4.4. Sim1M136K/+ mice generated severe obesity225 
The mice were kept in the single cage, fed a normal diet and the body weight was measured 
weekly. The N2 mice were weighed from the age of 10 weeks to the age of 26 weeks and the 
N3 mice were weighed from 6 to 11 weeks. The body weights of both N2 male and female 
Sim1M136K/+ mice were significantly (p<0.001) greater than those of Sim1+/+ mice (Fig. 10a,b). 
Besides, the body weight analysis of N3 mice of Obese-13 pedigree exhibited a significant 
increase of body weight of Sim1M136K/+ mice as early as 6 weeks of age (Fig. 10c). To 
measure the weight of epididymal fat we dissected the intra-abdominal white adipose tissue 
(WAT) of N3 mice at 12 weeks of age. An excessive accumulation of white adipose tissue 
was found in Sim1M136K/+ mice. The epididymal fat mass of Sim1M136K/+ mice was higher than 
that of Sim1+/+ mice at the age of 12 weeks (Fig. 10e). To investigate the serum leptin level 
of N3 mice, the blood serum was collected at 12 weeks of age. Consistent with a larger fat 
mass, Sim1M136K/+ mice had higher serum leptin levels when compared with Sim1+/+ mice 
(Fig. 10f).  
4.4.5. Sim1M136K/+ mice were hyperphagic225 
In order to measure the amount of food intake at the age of 8 weeks of N3 mice, we allowed 
the mice to take powdered food form a small food jar. After one week of habituation of 
feeding, at the age of 9 weeks the daily food intake was measured in every 24 hours for seven 
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consecutive days. The Sim1M136K/+ mice exhibited a significantly (p<0.001) increased daily 
food intake compared with Sim1+/+ mice (Fig. 10g).  
4.4.6. Sim1M136K/+ mice were pre-diabetic225 
At the age of 9 weeks of N3 mice, the blood glucose level was measured by collecting blood 
from the tail vein. Though the blood glucose level seems to be higher in Sim1M136K/+ mice 
than the Sim1+/+ mice, but statistically did not reach at significance (Fig. 10h). To investigate 
the serum insulin level blood serum was collected at the age 12 weeks of N3 mice. As for 
glucose metabolism, whereas Sim1M136K/+ and Sim1+/+ mice had almost similar blood glucose 
levels, but the serum insulin level of Sim1M136K/+ mice was significantly higher than that of 
Sim1+/+ mice (Fig. 10i). The similar blood glucose level in obese pedigrees may be the result 
of compensation by the high insulin level. 
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Figure 10. Metabolic phenotypes of Sim1 mutant mice225. (a) At the age of 26 weeks, the 
N2 generation of Sim1M136K/+ male  mice (n = 13) showed higher body weight than Sim1+/+ 
male mice (n = 12). (b) At the age of 26 weeks, the N2 generation of Sim1M136K/+ female  
mice (n = 11) showed higher body weight than Sim1+/+ female mice (n = 13). (b) The 
increased body weight of N3 mice indicates early-onset obesity in Sim1M136K/+ mice (n=10) 
than the Sim1+/+mice (n = 19). * p < 0.05, *** p < 0.001, one-way repeated ANOVA 
followed by Tukey's post-hoc test. (d) Decreased level of Sim1 mRNA of Sim1M136K/+ mice (n 
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= 6) was observed than the Sim1+/+mice (n = 6). ) (e) The Sim1M136K/+ mice (n = 6) exhibited 
Increased epididymal fat weights than the Sim1+/+ mice (n = 6). (f) Increased serum leptin 
level was found in Sim1M136K/+ mice (n = 8) in comparing to the Sim1+/+ mice (n = 8). (g) The 
amount of daily food intake of Sim1M136K/+ mice (n = 6) was higher than that of Sim1+/+ mice 
(n = 6).  (h) Both  the Sim1+/+mice (n = 19) and Sim1M136K/+ mice (n = 10) exhibited almost 
similar blood glucose level. (i) The  Sim1M136K/+ mice (n = 8) exhibited higher serum insulin 
levels than Sim1+/+mice (n = 8). * p < 0.05, ** p < 0.01, *** p < 0.001, two-tailed t-test. Data 
are shown as the mean + s.e.m. 
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Table 2. Whole exome sequencing identifies non synonymous mutations within the 
mapped chromosomal regions225. 
Mouse ID Obese-10 A Obese-10 B Obese-13 A Obese-13 B  
Body weight  
(26 weeks) 
56.3 g 54.5 g 62.5 g 60.6 g 
Total reads 85,845,404 100.0% 74,370,332 100.0% 78,108,258 100.0% 84,534,362 100.0% 
Mapped reads 76,972,358 89.7% 66,530,500 89.5% 68,763,865 88.0% 73,595,915 87.1% 
Not mapped reads 8,873,046 10.3% 7,839,832 10.5% 9,344,393 12% 10,938,447 12.9% 
Average coverage of 
capture target regions 
93 80 81 86 
Minimum coverage of capture target regions 
5 X  97.2%  96.1%  96.3%  96.8% 
10 X  93.4%  90.7%  91.0%  92.3% 
20 X  81.3%  75.2%  75.8%  78.7% 
40 X  54.3%  46.4%  47.0%  50.3% 
80 X  25.6%  21.6%  22.0%  23.4% 
100 X  19.9%  17.1%  17.4%  18.3% 
Variants called 8,693 100.0% 7,393 100.0% 7,453 100.0% 7,818 100.0% 
After filtering against 
control 
626 7.2% 457 6.2% 443 5.9% 535 6.8% 
With amino acid 
change 
40 0.5% 31 0.4% 21 0.3% 29 0.4% 
Sec63 
(chr 10: 42816394) 
A/A A/A A/G A/G 
Sim1  
(chr 10: 50908536) 
T/T T/T T/A T/A 
Mc4r 
(chr:18: 66859918) 
A/T A/T A/A A/A 
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4.5. Quantitation of hypothalamic gene expression225  
In the assay of hypothalamic gene expression, we compared the levels of hypothalamic 
neuropeptide gene expressions of Sim1M136K/+ mice and Mc4r Y41X/+ mice with those of mice 
with diet-induced obesity (DIO). This assay was done to find out if there were changes in 
gene expression common to these three mouse models of obesity. The diet induced obesity 
(DIO) mice and control mice were fed a high-fat diet as well as a regular chow diet, 
respectively, for 9 weeks, starting at the age of 3 weeks (DIO mice, body weight 30.2 ± 0.4 
g), n = 9; chow mice, body weight 24.7 ± 0.3 g, n = 9). In this study, we examined the 
mRNAs of the following genes: Agrp, Avp, Crh, Ghrh, Mch, Npy, Orexin, Oxytocin, Pacap, 
Pomc, Somatostatin and Trh. A significant reduction of Avp mRNA expression was seen in 
all of the obese groups, whereas, there was no change in the expression of Crh, Mch, Npy, 
Pomc, and Somatostatin mRNAs levels (Fig. 11a,b) in comparing to their wild-type 
littermates. A reduced mRNA expression of Agrp was found in both Sim1M136K/+ mice and 
DIO mice than their wild-type littermates. The Sim1M136K/+ mice exhibited a significant 
reduction in Orexin, Oxytocin and Trh mRNAs in comparing to the Sim1+/+ mice. 
Particularly, a drastic reduction (90%) of  Oxytocin mRNA was observed in Sim1M136K/+ mice 
than the Sim1+/+ mice.  Whereas, a significantly reduced level in Ghrh and Pacap mRNAs 
were found only in DIO mice (Fig. 11a,b). 
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Figure 11. Hypothalamic neuropeptide/gene expression in three mouse models of 
obesity225. (a) Measurement of hypothalamic neuropeptide gene expression in Mc4r+/+ (n = 
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9), Mc4rY41X/+ (n = 9), Sim1+/+ (n = 9), Sim1M136K/+ (n = 9), along with high-fat-diet-induced 
obesity (DIO) mice (n = 9) and mice fed a regular chow diet (n = 9). For each comparison  
values are indicated as compared to the average of the control groups. (b) Altered profiles of 
neuropeptide gene expression of the three models of mouse obesity. * p < 0.05, ** p < 0.01, 
*** p < 0.001, two-tailed t-test with Bonferroni correction for multiple comparisons. Data are 
shown as the mean + s.e.m.  
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Chapter 5. 
Discussion 
 
In this forward genetic study, in parallel with the screening of ENU-mutagenized mice for 
sleep/wake disorder, we have screened the mice to identify any genetic mutation responsible 
for obesity. This study was performed through the dominant screening, using C57BL/6 
substrains. Throughout the screening of more than 5000 mutagenized G1/F1 mice, we have 
successfully established two different obese pedigrees  i.e., Obese-10 and Obese-13, having a 
single point mutation in Mc4r gene and Sim1gene respectively.  Though, several ENU-
mutagenesis process were succeed to establish obesity pedigree39,85,86 through the recessive 
screening, but there is no recognized evidence of successful dominant screening to establish 
an obesity pedigree. Thus, this is the first successful dominant screening for obesity. 
One of the main reasons of success of this dominant screening may be the mating mouse 
strains. In this dominant screening, we used ENU induced B6J male and counter strain 
B6J/B6N wild-type female to generate G1/F1 mice. As each individual G1/F1 animal was 
heterozygous for a unique set of induced mutations, dominant phenotypes were then 
identified in N2 mice by further breeding using B6N wild-type female as a counter strain. 
The parent mating mice (B6J and B6N) of F1 mice have almost same QTLs in relation to 
body weight, same genetic backgrounds, metabolic characteristics and almost phenotypes are 
similar among the strains40,224. Thus, it has a high possibility to cause a clear phenotypic 
difference between mutant group and wild-type group and seems to be easy to identify the 
single candidate mutation caused by ENU mutagenesis through the dominant screening for 
obesity. Consequently, this very simple and efficient dominant mating scheme rapidly 
provides genome-wide coverage for dominant mutations and gives useful information for  
forward genetics that is difficult to obtain with reverse genetics approaches.  
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 The obese mice are allied with infertility and it is difficult to produce new progeny  through 
natural mating using obese mice. In a dominant screening, the dominantly inherited obesity  
mice exhibits severe obesity, also suffered from infertility and unable to produce progeny 
through the natural mating48,242. If the mating mice are suffering from low fertility, the in 
vitro fertilization method is necessary to use for the production of new progeny48. As the 
obese mice of Obese-10 and Obese-13 were mostly unable to perform natural mating, we 
have used in vitro fertilization method to generate the next generation. The subsequent 
linkage analysis and whole exome sequencing easily helps to detect the mutations in the  
chromosomal region of the target phenotype. According to and the number of non-
synonymous mutations and available mutation rates87,243 the ENU treated mice progeny 
exhibit 50-70 mutations. Accordingly, we found 20-40 non-synonymous mutations in the N2 
progeny of Obese-10 as well as Obese-13 pedigrees (Table 2). Thus, this dominant screening 
of obesity showed an opportunity in forward genetics strategy using C57BL/6  substrains for 
mutagenized and counter strain, in vitro fertilization method for the production of new 
progeny and whole exome sequencing to identify mutations in the chromosomal region of a 
target phenotype. The number of non-synonymous mutations in the N2 progeny of Obese-10 
as well as Obese-13 pedigrees (Table 2) would be decreased, if we could perform a fine 
linkage analysis. The finesse of linkage analysis within the mapped chromosomal region 
linked to the target phenotypes depend upon number of SNPs marker that is used. Though 
there has been 17,000 SNPs between B6J and B6N41 but we were  able to use only 4 SNPs 
markers within the target region of  chromosome 18 (Obese-10) and 6 SNPs markers within 
target region of chromosome 10 (Obese-13). If we can increase the number SNPs markers 
within the mapped region, it may more helpful to perform more successful linkage analysis. 
Among the 13 most obese G1/F1 mice, those have been selected to test the heritability of 
obesity, only two pedigrees successfully established heritability of obesity. Though the other 
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11 G1/F1 mice had overweight, but they could not establish the heritable obesity. The reason 
may be the lacking of availability of any strong obesogenic effect caused by a single gene 
mutation35. Moreover, it can be hypothesized that the obesity of the other 11 G1/F1 mice was 
developed by chance or may be associated with the combined effects of weak obesogenic 
mutations or due to the random fluctuations in body weight. On supporting to this evidence 
we found that the distribution of body weight of the G1/F1 mice tends to skew toward 
overweight (Fig. 3b).  
Further, the funders F1 mice of Obese-10 pedigree as well as the Obese-13 pedigree were the 
two heaviest mice among the 5000 mice that we have screened. Though, we cannot indicate 
these body weight as a standard scale at which dominant screening will be succeeded but, we 
can assume that the mutation of their (F1 mice of Obese-10 pedigree and Obese-13 pedigree) 
candidate gene may be affected strongly to generate obesity than the other relevant causes. 
Otherwise, it is very difficult to detect gene mutations throughout a dominant screening, in 
case of moderate or weak obesity. 
In this research, the single point mutation in Mc4r gene, occurred in the Mc4rR41X/+ mice of  
Obese-10 pedigree, caused the transversion of amino acid tyrosine to a premature stop codon 
(Tyr-41-Stop), generated a loss of function of Mc4r gene and contributed to increase body 
weight of Mc4rR41X/+ mice.  Mutation of the Mc4r gene plays a major role in generating 
obesity both in rodents and human211,244,245. Heterozygous Mc4r null mutant mice exhibit 
obesity phenotype associated with hyperphagia and hyperleptinemia235.  
Leptin is secreted from the high amount of adipose tissue and hyperleptinemia is commonly 
observed in human obesity and animal models246–248. The increased level of serum leptin is 
correlated with the increased adipose mass249. The increased daily food intake in obese mice 
proposes the resistance of leptin mediated energy expenditure250. With the increase of body 
weight, insulin secretion also increases in the basal state251. Heterozygous Mc4r null mutant 
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also reveals obesity phenotype allied with hyperinsulinemia235. Thus, the increased metabolic 
characteristics in the Mc4rR41X/+ mice of  Obese-10 pedigree, showed a correlation with the 
Mc4r mutant human and rodents. Besides, the increased insulin level, but no change in blood 
glucose level in Mc4rR41X/+ mice suggests for maintaining normal blood glucose levels by 
compensating with increased insulin levels.  
In order to measure the protein level we have performed western blotting for brain 
homogenates using MC4R antibodies from two companies (Abcam #ab24233; Alomone labs 
#AMR-024), but it turned out that both antibodies cross-react a variety of brain proteins so 
that it is very difficult to examine MC4R protein in brain homogenates due to too many 
background bands. In general and based on our experience, there are few good antibodies for 
GPCR such as MC4R protein. Actually, there have been no report of western blot for MC4R 
of MC4R-deficient mice. 
Sim1 is expressed in the paraventricular (PVN), supraoptic (SON), and anterior 
periventricular (aPV) nuclei of the hypothalamus for terminal migration and differentiation of 
the neurons in these region. Thus, the disruption of Sim1 affects the development of several 
neurosecretory lineages in the region of SON, PVN, and aPV207.  Mice homozygous for a null 
allele of Sim1 (Sim1-/-) die perinatally due to the failure of forming PVN, SON and aPV220. 
Where as Sim1+/-  mice are viable but carrying developmental defect of PVN associated with 
early onset obesity, hyper leptinemia and  insulinemia, increased linear growth240.We can 
detect this defect in Sim1+/- mice comparing with the wild-type littermates through 
quantitative histological analysis at the age of 8 weeks. A quantitative histological analysis 
demonstrates a 24% fewer cells of PVN in Sim1+/- mice compare to the wild-type 
littermates240. The in situ hybridization can detect the SIM1 transcript or the 
immunocytochemistry using a polyclonal SIM1 antiserum can detect SIM1 protein in the 
hypothalamic SON, PVN, and aPV207. Mutation of Sim1 gene produced in adult mice also 
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develop obesity. Conditional inactivation of Sim1 gene in the region of hypothalamic neurons 
of adult mice was generated using a neural specific Cre transgene (CaMK-CreERT2), which is 
induced by Tamoxifen and observed that the hypothalamic circuit involve in the increase of 
body weight in high fat diet feeding condition with no change of energy expenditure220. The 
neuropeptides of paraventricular nucleus in the conditional Sim1 mutant adult mice exhibits a 
similar change to those of heterozygous Sim1 mutant (Sim1+/-) mice216.  
In this study, the other single point mutation in Sim1 gene, occurred in the Sim1M136K/+ mice 
of  Obese-13 pedigree, caused the transversion of amino acid from methionine to lysine (Met-
136-Lys), located in the exon 4 of Sim1 gene in obese mice. This change of amino acid 
generated a change of its protein structure and produced SIM1 (M136K) protein having total 
lacks of transcriptional activity and contributed to increase body weight of Sim1M136K/+ mice.  
Sim1 haploinsufficiency, both in human and mice is associated with severe 
obesity212,240,252,253. Obesity generated by Sim1 deficiency is hyperphagic and showed a 
critical regulatory effect on energy expenditure215,241,254. Hyperleptinemia is correlated with 
increased adipose tissue and is associated with Sim1 haploinsufficient mice240. 
Hyperinsulinemia is correlated with Sim1 haploinsufficiency mice240. Thus, the increased 
metabolic characteristics in the Sim1M136K/+ mice of Obese-13 pedigree, exhibited a 
correlation with the results of Sim1 mutant human and rodents. Besides, the increased insulin 
level, but no alteration in blood glucose level in Sim1M136K/+ mice suggests for maintaining 
the normal blood glucose level by compensating with increased insulin levels.  
Due to the presence of bHLH (basic helix-loop-helix) and PAS (Per-Arnt-Sim) domain SIM1 
acts as a critical transcriptional factor and strongly expressed in the development of the 
PVN207. By using the PAS domain wild-type SIM1 binds with ARNT2 to form a hetero-
dimer and exerts a strong transcriptional activity for functioning in the development of the 
hypothalamus208. The function of the PAS domain in regulation of the dimerization activity 
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of the bHLH domain. If any change or mutation in any member of  PAS domain it loses its 
functional activity. Mutant SIM1 protein exhibits a decrease in transcriptional activity228. 
Accordingly, the  SIM1(M136K) protein in Sim1M136K/+ mice of Obese-13 pedigree exhibited 
its loss of function in the luciferase reporter assay. Besides, the SIM1(M136K) protein failed 
to change the transcriptional activity of the SIM1 wild-type:ARNT2 dimer suggests that the 
SIM1(M136K) protein does not have a dominant negative effect. With the increase amount of 
wild-type SIM1 protein, it exhibits an increased transcriptional activity, but the 
SIM1(M136K) protein did not. This finding demonstrates that, the SIM1 (M136K) protein 
completely loses its transcriptional activity. 
In the Obese-13 pedigree, along with the Sim1 gene mutation, we also found a non-
synonymous heterozygous mutation in Sec63 gene in the obese mice. The gene Sec63 works 
with the Sec61 translocon and HSPA5 in facilitating the “cotranslational” translocation across 
the endoplasmic reticulum (ER) membrane255. The Sec61 complex is known as the central 
component of the protein translocation apparatus of the endoplasmic reticulum membrane. In 
addition, the Sec61-Sec62-Sec63 complex may perform post-translational protein 
translocation into the  endoplasmic reticulum256. Mutations of Sec63 gene have been 
associated with autosomal dominant polycystic liver disease229. Liver or kidney specific 
inactivation of Sec63 gene resulted in liver or polycystic kidney disease, respectively. 
Knockout mice of Sec63 gene increased the severity of cyst formation255. But, we did not find 
any liver and kidney dysfunction or cyst formation in the obese mice of this Obese-13 
pedigree. Although several studies have been done, but, none of these literature explained any 
relation of Sec63 gene mutation with the obesity. Though, we cannot refute the possibility of 
having any effect of Sec63 gene mutation in causing obesity, but there is no any evidence 
behind the genetic links between obesity and Sec63 gene. 
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Many of hypothalamic genes/neuropeptides play an important role in food intake and energy 
expenditure106. The Mc4r gene also expressed in a number of hypothalamic sites, including 
the dorsomedial, lateral, ventromedial and paraventricular nuclei198 and contributes in 
regulating feeding behavior192. A significant reduction of Avp mRNA expression was found 
in  the hypothalamus of Mc4rR41X/+ mice, along with the Sim1M136K/+ mice and DIO mice. The 
reduced Avp mRNA level in all three obese groups may be due to the hypothalamic posterior 
pituitary dysfunction caused by abnormal endogenous opioids257 or due to the any other 
secondary effect of obesity such as increased leptin and insulin level in obese mice258.  
Sim1 gene is necessary for the development of PVH neurons and developmental defects in 
PVN results obesity in Sim1 haploinsufficient mice207,240. As the SIM1 is a transcription 
factor and haploinsufficiency of SIM1 may affect the transcription level of target genes207. 
The decreased mRNAs expression of Oxytocin, Trh, Avp & Agrp in Sim1M136K/+ mice may be 
due to the lack of transcriptional activity, which is consistent with of SIM1 haploinsufficient 
mice215,216,220,259. As Orexin is expressed in the LHA, and SIM1 does not express in LHA. 
Thus the decreased expression of Orexin mRNA in Sim1M136K/+ mice may not be the direct 
results of disrupted transcriptional activity of the mutant SIM1 protein. Instead, it may be due 
to the high leptin level or due to a secondary change based on the tight reciprocal fiber 
connections between the maldeveloped PVN of Sim1M136K/+ mice and Orexin neurons260.  
In order to confirm the change of hypothalamic gene expression due to the obesogenic effect, 
we used high fat diet induced B6J male mice. The DIO male B6J mice are a suitable model 
for investigating non-genetic mechanisms of obesity, as well as for recognizing the major 
changes in the hypothalamic expression of genes261. Besides, the DIO mice would be a nice 
model for human obesity in which high-calorie food is intensely used. Long time use of high-
fat diet in mice generates leptin-resistance85,262. No change in expression of Pomc mRNA but 
a significant reduction of Ghrh mRNA and Agrp mRNA expression was found in high fat 
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diet feeding mice263–266. This result is consistent with reduction of Ghrh mRNA and Agrp 
mRNA expression in our DIO mice. Thus, the common changes of Agrp mRNA expression 
between the Sim1M136K/+ mice and the DIO mice may be the result of the secondary 
obesogenic effect associated with the increased insulin and leptin levels258. As we know, 
ghrelin stimulates Ghrh secretion from the hypothalamus267 and obesity is characterized by 
markedly decreased of ghrelin. The significant reduction of Ghrh in obese as compared to 
lean controls is due to the ghrelin resistance in obese individuals268,269. Again, the high fat 
diet also changes the behavioral activity beside the generation of obesity270. Thus, the change 
of Pacap and Ghrh mRNAs can be considered the result of behavioral changes beyond the 
metabolic changes in DIO mice. Therefore, it can be suggests that, through a different pattern 
of hypothalamic gene expression, each obesity models of this study represents the 
involvement of their hypothalamic genes in generating obesity. 
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Chapter 6. 
Conclusion                                                        
 
In summary, through the dominant screening of forward genetic study using ENU-
mutagenesis and C57BL/6 substrains, we have identified Sim1 and Mc4r gene mutations 
among very few genes, which cause obesity via haploinsufficiency. In most cases the human 
obesity caused by gene mutation is dominantly inherited194,271. Therefore, the knockout mice 
of Sim1 and Mc4r gene cannot be the complete model of obesity that is found in human 
because, the knockout mice are completely lacking of protein of the target gene. Instead, 
identification as well as characterization of mutations produced by ENU-mutagenesis in mice 
will direct, the better understanding of the obesity associated with human gene mutation39. 
Thus, the dominant screening of forward genetic strategy using the C57BL/6  substrains as an 
ENU mutagenized and counter strain would be a good choice to identify the responsible gene 
in obesity research as well as in the research of any other disease, which is caused by gene 
mutation. 
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